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Macular telangiectasia type 2 is a bilateral disease of unknown cause with characteristic alterations of
the macular capillary network and neurosensory atrophy. Its prevalence may be underestimated and
has recently been shown to be as high as 0.1% in persons 40 years and older. Biomicroscopy may show
reduced retinal transparency, crystalline deposits, mildly ectatic capillaries, blunted venules, retinal
pigment plaques, foveal atrophy, and neovascular complexes. Fluorescein angiography shows telangi-
ectatic capillaries predominantly temporal to the foveola in the early phase and a diffuse hyper-
ﬂuorescence in the late phase. High-resolution optical coherence tomography (OCT) may reveal
disruption of the photoreceptor inner segmenteouter segment border, hyporeﬂective cavities at the
level of the inner or outer retina, and atrophy of the retina in later stages. Macular telangiectasia type 2
shows a unique depletion of the macular pigment in the central retina and recent therapeutic trials
showed that such depleted areas cannot re-accumulate lutein and zeaxanthin after oral supplemen-
tation. There have been various therapeutic approaches with limited or no efﬁcacy. Recent clinical trials
with compounds that block vascular endothelial growth factor (VEGF) have established the role of VEGF
in the pathophysiology of the disease, but have not shown signiﬁcant efﬁcacy, at least for the non-
neovascular disease stages. Recent progress in structureefunction correlation may help to develop
surrogate outcome measures for future clinical trials.
In this review article, we summarize the current knowledge on macular telangiectasia type 2,
including the epidemiology, the genetics, the clinical ﬁndings, the staging and the differential diagnosis
of the disease. Findings using retinal imaging are discussed, including ﬂuorescein angiography, OCT,
adaptive optics imaging, confocal scanning laser ophthalmoscopy, and fundus autoﬂuorescence, as are
the ﬁndings using visual function testing including visual acuity and fundus-controlled microperimetry.
We provide an overview of the therapeutic approaches for both non-neovascular and neovascular
disease stages and provide a perspective of future directions including animal models and potential
therapeutic approaches.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Contents
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Macular telangiectasia (MacTel) type 2 is a bilateral disease of
unknowncausewith characteristic alterationsof themacular capillary
network and neurosensory atrophy. The disease manifests initially
temporal to the foveal center, but may later encompass an oval area
with a radius of about6 horizontally and5 vertically centered on the
foveola. Symptoms typically start in the ﬁfth or sixth decade of life.
Some patients have a positive family history. Possibly due to low
disease awareness, both amongst clinicians and patients, the diag-
nosis of MacTel is often delayed. It may also be misdiagnosed as age-
related macular degeneration in the presence of neovascularization.
Beginning in 2005, the Macular Telangiectasia Project (“MacTel
Project”; http://www.mactelresearch.org) has initiated major
research activity on MacTel type 2. In an effort involving a number
of clinical centers and basic science laboratories, this privately
funded project aims to develop a better understanding of the
clinical features and natural history of the disease, to elucidate
a genetic association, to identify animal models which may
improve the understanding of intrinsic pathogenetic mechanisms,
and ultimately, to identify and test potential treatments.
This increased research interest in MacTel type 2 has helped to
gain new insights in the disease in several ways. Characteristic
phenotypic ﬁndings have been identiﬁed using various imaging
techniques that now allow an improved clinical differentiation ofthis entity from other retinal diseases. Moreover, the description of
affected but asymptomatic family members of patients together
with the higher than expected prevalence in population based
studies should clearly increase the awareness of the disease.
In this review, updated phenotypic characterization of MacTel
type 2 including morphologic data (derived from retinal imaging
and histopathology), data on retinal dysfunction, epidemiology,
genetics, together with a review of likely pathogenic mechanisms
and attempted treatments are provided.
2. Terminology
A variety of terms have been used for MacTel type 2. The ﬁrst
description of the disease was likely a short report of Donald Gass
on “bilateral paracentral capillary telangiectasia of unknown cause”
(Gass, 1977) followed by a case series on “focal parafoveal retinal
telangiectasis” (Hutton et al., 1978) which further characterized the
disease as a distinct clinical entity with familial occurrence. The
term “retinal telangiectasis” was introduced earlier by Reese to
describe various retinopathies characterized by dilated and
incompetent vessels (Reese, 1956). However, his case series, as well
as a later ﬂuorescein angiographic study on retinal telangiectasis
(Gass, 1968), did not include MacTel type 2.
In a revised version of an earlier publication (Gass and Oyakawa,
1982), Gass and Blodi classiﬁed various disease entities with ectatic
P. Charbel Issa et al. / Progress in Retinal and Eye Research 34 (2013) 49e77 51retinal vessels of unknown origin at the posterior pole (Gass and
Blodi, 1993). Based on phenotypic differences, they identiﬁed
three distinct groups (and additional sub-forms) of “idiopathic
juxtafoveolar retinal telangiectasis” (Table 1) that were suggested to
differ in their pathophysiology. These idiopathic diseases should be
distinguished from similar vascular alterations that may be caused
by diseases such as retinal vein occlusion, vasculitis, diabetes,
carotid occlusive disease or radiation therapy. Group 2A of Gass and
Blodi’s revised classiﬁcation is equivalent to MacTel type 2.
To characterize the localization of the vascular alterations in
MacTel type 2, authors later used terms such as para-, peri-, and
juxta-foveal or -foveolar. According to Hogan et al., the fovea covers
the central w1.5 mm and the foveola the central w200 mm of the
retina (Hogan et al., 1971). A terminology implying “close to” (para-,
peri-, juxta-) as topographic reference would limit the disease
process to an area in direct vicinity to the respective anatomical
landmark, excluding the fovea or foveola. However, the neurosen-
sory disease process in MacTel type 2 involves the foveal center and
capillaries directly bordering the foveal avascular zone.
The macula as a topographic reference is a more comprehensive
descriptive term for the localization of retinal alterations in MacTel
type 2. Although the macular area is not deﬁned consistently in the
literature, it would refer to a central retinal area including the
foveal center. Consequently, recent publications used the term
“macular telangiectasia”. The abbreviation “MacTel” was chosen as
the acronym for the Macular Telangiectasia Project. Despite the
increasing evidence for a secondary origin of the vascular alter-
ations, we suggest to keep this descriptive nomenclature, at least
for the time being. It is furthermore suggested that the categori-
zation into different groups (Gass and Blodi, 1993; Gass and
Oyakawa, 1982) is renamed as “types”, in order to emphasize the
phenotypic and pathophysiologic difference. A new terminology
might be considered once the various phenotypes presenting with
idiopathic macular telangiectasia have been better characterized,
and once there is more clarity about the pathophysiology and the
genetic background of the diseases.3. Epidemiology
The prevalence of MacTel type 2 has so far been analyzed in four
population-based studies from three continents. Two populations
included mainly Caucasians from the United States and Australia,
and two others included Africans from Kenya and Nigeria. Data
from the Beaver Dam study in the US (cohort: 4790 people, 43e86
years of age) suggest a prevalence of 0.1% in the age group analyzed
based on grading from stereoscopic mydriatic fundus photographsTable 1





Unilateral, visible telangiectasia, macular edema,
hard exudates/considered developmental anomaly
Males 4
Bilateral, occult telangiectasia, minimal exudation,
foveolar atrophy, superﬁcial retinal crystalline
deposits/considered to be acquired
Males ¼ females 50e6
w1
Bilateral, visible telangiectasia, minimal exudation,
progressive obliteration of the perifoveolar
capillary network capillary occlusion, optic disc
pallor/considered to be acquired
Inconclusive 5(Klein et al., 2010). Data from the Melbourne Collaborative Cohort
Study in Australia suggested a lower prevalence, estimated to range
from 0.004 to 0.022% based on non-mydriatic digital macular
images (just over 22,000 participants, mean age of 65 years) (Aung
et al., 2010). As noted by Klein et al., this lower prevalence estimate
might be due to different methodology in the grading of the fundus
photographs. The Beaver Dam Eye Study fundus photographs were
entirely re-assessed while the Australian images were only graded
speciﬁcally for MacTel type 2 if a previous grading had suggested at
least one feature of the disease (Klein et al., 2010). Analysis of digital
non-mydriatic fundus images from Kenya and Nigeria (together
8599 participants) suggested a prevalence of 0.06 in both countries
(95% conﬁdence interval 0.02e0.21% and 0.01e0.17%, respectively),
with an estimated combined rate of 0.06 (95% conﬁdence interval
0.02e0.14%) (Sallo et al., 2012a). Similar to the analysis from the
Beaver Dam Eye Study, all imageswere re-assessed for the presence
of MacTel type 2.
Notably, the true prevalence is likely to be underestimated in all
four analyzed populations due to a grading based solely on color
fundus images. More advanced imaging technologies were not
used, such as ﬂuorescein angiography, optical coherence tomog-
raphy or confocal scanning laser ophthalmoscopy imaging
including fundus autoﬂuorescence, that have been shown to be
more sensitive in detecting early and/or asymptomatic disease
stages of MacTel type 2 (Gillies et al., 2009).
Gender distributionwas without a clear predilection in the large
cohort (n ¼ 92) reported by Gass and Blodi (1993). The proportion
of women in the baseline report of the MacTel multicenter study
(n ¼ 310) is 64% (Clemons et al., 2010). The mean age of patients at
enrolment in the MacTel study was 61 years (SD, 9 years) and
mean age at diagnosis was 57 (SD, 9 years) (Clemons et al., 2010).
Currently, no reliable data are available on the time of onset of
symptoms.4. Inheritance and genetics
The bilaterality of the disease together with the occurrence in
monozygotic twins (Gillies et al., 2009; Hannan et al., 2007;
Menchini et al., 2000; Siddiqui and Fekrat, 2005) as well as in
siblings and families (Chew et al., 1986; Delaere et al., 2011; Gass
and Blodi, 1993; Gillies et al., 2009; Hutton et al., 1978; Isaacs and
McAllister, 1996; Oh and Park, 1999; Parmalee et al., 2012)
suggests genetic factors in the pathogenesis of MacTel type 2.
Vertical transmission in families suggests a dominant inheritance.
As part of the MacTel project, 17 pedigrees with multiple affected
family members were identiﬁed out of a large cohort of patientso the classiﬁcation by Gass and Blodi (1993).
Group Sub-type
0 1 A Involved area > 2 clock hours




Stage 1 Diffuse hyperﬂuorescence in late
phase ﬂuorescein angiography
Stage 2 Reduced parafoveolar retinal
transparency
Stage 3 Dilated right angled venules
Stage 4 Intraretinal pigment clumping
Stage 5 Vascular membranes




Prevalence of macular alterations in patients with macular telangiectasia type 2. The
frequency indicated in the left column is based on clinical experience. Percentages in
the middle and right columns are based on analysis of fundus photographs of the
two largest patient cohorts reported (Clemons et al., 2010; Gass and Blodi,1993). The
frequency of these clinical ﬁndings in other reported cohorts may vary depending on
the distribution of disease stages in the studied cohort. Neovascular complex may be
associated with hemorrhage, cystoid edema, exudates, and eventually scarring.
*Frequent in late disease stages; n.r. ¼ not reported.
Funduscopic sign Frequency








Crystalline deposits Frequent 38% 21%
Ectatic capillaries Frequent 64% 51%
Blunted/dilated retinal vessel Medium* 34% 29%/25%
Foveal atrophy Medium* 13% n.r.
Pigment-hypertrophy Medium* 41% 33%
Yellow foveal spot Rare 3% n.r.
Retinal hemorrhage in absence
of a neovascular complex
Rare n.r. n.r.
Atrophy of the RPE Rare n.r. n.r.
Lamellar or full thickness
macular hole
Rare n.r. n.r.
Neovascular complex Rare 14% 2%
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dominant segregation with reduced penetrance (Parmalee et al.,
2012). Moreover, there appears to be variable expressivity as sug-
gested by the different clinical disease stage of a monozygotic twin
pair (Gillies et al., 2009). Environmental and epigenetic factors,
and/or gene-gene-interactions thus may also play a role in the
development of the disease phenotype.
So far, candidate-gene screening approaches to identify
a genetic defect responsible for MacTel type 2 have been unsuc-
cessful (Parmalee et al., 2010; Szental et al., 2010). Subsequent
genome-wide linkage analysis identiﬁed a single peak on chro-
mosome 1 at 1q41-42 (Parmalee et al., 2012). However, sequencing
of 14 candidate genes within the 15.6 Mb region did not identify
causal variants. Certainly, discovery of a disease-causing genetic
defect would have an impact on further research on MacTel type 2,
particularly on identiﬁcation and understanding of pathogenetic
pathways, new therapeutic approaches, and the development of
relevant animal models.
5. Clinical ﬁndings
Since funduscopic ﬁndings early in the disease course may be
very subtle, thorough biomicroscopy is necessary. Bilaterality is
characteristic for MacTel type 2. Although biomicroscopic features
are usually rather symmetric, they may be more advanced in one
eye than the other (Clemons et al., 2010). Therefore, the few re-
ported unilateral cases may exhibit an asymmetric disease with
very mild and hardly discernible changes in the apparently unaf-
fected eye (Bruè et al., 2011). The retinal alterations typical for
MacTel type 2 usually begin in a temporal paracentral area. They
may eventually affect a characteristic oval region within about one
disc diameter eccentricity from the foveal center, where the hori-
zontal diameter is larger than the vertical diameter. The horizontal
raphe is not respected by the disease process. Despite the angio-
graphic leakage, there is generally no biomicroscopic or angio-
graphic evidence of prominent cystoid macular edema.
In case of a circular involvement, alterations are usually most
pronounced on the temporal side. In a small series, Abujamra and
co-workers divided the macula into four quadrants. MacTel type 2
related alterations were predominantly identiﬁed in the temporal
inferior quadrant, followed by the temporal superior, and the nasal
quadrants (Abujamra et al., 2000). Such an epicenter of the disease
temporal or temporal inferior to the foveal center is also suggested
bymicroperimetry and OCT studies that assessed the localization of
functional and structural alterations (Barthelmes et al., 2008a;
Charbel Issa et al., 2007a).
Some patients may present with late disease manifestations in
the temporal macula while the nasal side is largely unaffected. In
this respect, it should be noted that progression from a sectorial to
a circular involvement has not convincingly been shown longitu-
dinally, and it might be that different subtypes are involved.
The followingmacular alterationsmay be found funduscopically
in eyes with MacTel type 2 (summarized in Table 2 and Fig. 1):
 Blunting or lack of the foveolar reﬂex may be observed early in
the disease course. Later, it is regularly absent. However, this is
not uncommon in older patients, and very early disease stages
may thus appear normal on funduscopy (Fig. 1A,B).
 Reduced retinal transparency (“retinal graying”) in the parafo-
veolar areamay be the ﬁrst ophthalmoscopically visible change
and is a hallmark of the disease (Fig. 1CeG). The graying may
vanish with progressing neurosensory atrophy in later disease
stages. The cause of the retinal graying is yet to be determined,
however, if Müller cell dysfunction occurs early in the disease
(see Chapter 14.3), then the observations may be relevant thatMüller cells may act as light transmitting ﬁbers (Franze et al.,
2007) and that they are involved in retinal ﬂuid and ion
homoeostasis (Bringmann et al., 2006). Other factors that may
be involved in loss of macular transparency may be structural
changes within the neurosensory retina leading to increased
light scatter, such as mild extracellular and/or possibly intra-
cellular edema.
 Crystalline deposits (Fig. 1E,G,I) are located in the inner retina at
the level of the inner limiting membrane (Gass and Blodi,
1993). In pronounced cases, they may be detected in OCT
scans where they appear as hyperreﬂective dots at the anterior
surface of the nerve ﬁber layer, arranged along the nerve ﬁbers
(Baumüller et al., 2010; Sallo et al., 2011). Crystalline deposits
may be present in virtually all disease stages (Gass and Blodi,
1993; Moisseiev et al., 1990; Sallo et al., 2011). In an analysis
of data derived from the MacTel study, 46% (203 out of 443) of
patients had crystalline deposits, of which 60% occurred
bilaterally (Sallo et al., 2011).
 Mildly ectatic capillaries commonly become visible in stage 3
(see Chapter 8) and were described to affect mainly the deeper
capillary network (Gass and Blodi, 1993). However, others
identiﬁed telangiectatic vessels in both the inner and outer
retinal circulation (Yannuzzi et al., 2006). Although rather
commonly observed funduscopically, this alteration may be
difﬁcult to detect on fundus photographs.
 Blunted, slightly dilated venules (Fig. 1F), of which there may be
one or several, are often associated with ectatic capillaries and,
in later disease stages, with pigment-hyperplasia. These vessels
appear not to narrow towards the foveola and suddenly seem
to dive at a right angle into the deeper retinal layers. The
venules might become dilated as a result of increased blood
ﬂow in the paracentral telangiectatic capillaries.
 Foveal atrophy may appear as small foveal non-prominent
cysts, simulate a lamellar macular hole (“pseudo-lamellar
macular hole”; Fig. 1G), or may only present with a slightly
altered foveal reﬂectivity. Cysts and pseudo-lamellar macular
holes are mostly associated with inner retinal cavities visible
on OCT (see Chapter 6.2). They may be round or slightly
irregular and may be slightly decentered temporally. Some-
times, two ormore of these small lesionsmay be distinguished.
Fig. 1. Clinical ﬁndings and corresponding early (respective upper frame) and late (respective lower frame) ﬂuorescein angiography in patients with MacTel type 2. All ﬁndings are most
pronounced temporal to the foveola, butmayencompass a central oval area. Staging is usedaccording to theGass&Blodi classiﬁcation.A,B) Stage 1with onlymild angiographic leakage and
notypical funduscopicﬁndings.C,D)Stage2with loss of retinal transparency (“retinal graying”)C)only temporal to the foveolaorD)within theentire paracentral area.E) Foveal yellowspot
ina stage2eyewithpronounced crystallinedeposits.F)Stage 3with abluntedretinal venule.GeJ)Stage4with variousmanifestationsof pigmentproliferation.G)Earlypigmentations; note
also the pseudo-lamellar hole, the graying and the crystalline deposits. H) Pigment proliferation without obvious other ﬁndings characteristic for MacTel type 2. I,J) Retinal pigment
proliferations with different degrees of surrounding RPE-atrophy. Some graying and crystalline deposits are seen in I).
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accompanying epiretinal gliosis. Atrophy affecting the outer
retinal photoreceptor layer appears to be the natural endpoint
of the disease. There may be thinning and/or loss of the
photoreceptor layer, sometimes presenting as outer retinal
cavities (see Chapter 6.2 on OCT imaging). Atrophy of the
photoreceptor layer may enlarge over time and results in
localized loss of function, but this development may remain
rather unremarkable funduscopically. Pseudo-lamellarmacular
holes (only 14 out of 184 eyes in series reported by Gass and
Blodi) and foveal atrophy are most likely underreported since
they may easily be missed on fundus photography.
 Retinal pigment plaques (pigment-hyperplasia; Fig. 1HeJ) are
often associated with blunted tips of dilated venules (Gass and
Blodi, 1993). They appear to originate from small foci of
hyperplasia (Fig. 1G) of the retinal pigment epithelium cells
that subsequently migrate into the neurosensory retina. Atro-
phic changes in the photoreceptor layer seem to precede and
thus promote pigment-hyperplasia, which is in line with the
observation that retinal pigment plaques are always associated
with an absolute scotoma (see Chapter 7). Therefore, the
pathophysiology may be similar to bone spicule-like pigmen-
tation in retinitis pigmentosa: an accordant mouse model
where photoreceptor atrophy with resulting direct contact
between retinal vessels and the retinal pigment epithelium is
associated with intraretinal pigment migration around retinal
vessels (Jaissle et al., 2010). Sometimes, retinal pigment pla-
ques may be surrounded by RPE atrophy (Fig. 1J).
 A round yellow spot (Fig. 1E), ﬁrst described as a central vitel-
liform lesion of around 1/2-disc-diameter-size, may rarely be
found centered on the fovea. Increased fundus AF and sub-
foveal accumulation of photoreceptor debris may be associated
with such yellowish spots (see Chapters 6.2, 6.6 and 11), sug-
gesting an accumulation of ﬂuorophores, e.g. subretinal accu-
mulation of photoreceptor outer segment debris or increased
lipofuscin in the retinal pigment epithelium. The pseudovi-
telliform lesion described by others (Margalit et al., 2002) most
likely refers to the same clinical ﬁnding.
 Small retinal hemorrhages may rarely occur in absence of
a neovascular complex (see below) and usually resolve within
several weeks.
 True lamellar or full thickness macular holes, which may present
a complication during the natural disease process, have been
reported in individual patients and may be conﬁrmed by OCT
imaging (Albini et al., 2006; Charbel Issa et al., 2009c; Gass and
Blodi, 1993; Gass and Oyakawa, 1982; Gregori and Flynn, 2010;
Koizumi et al., 2007b; Olson and Mandava, 2006; Patel et al.,
1988; Shukla, 2011; Shukla and Venkatesh, 2012). The patho-
genesis may involve a progressive degeneration and atrophy of
neurosensory cellular elements leading to instability of the
foveal structure, possibly rendering surgery less effective than
it is for other types of macular hole. Notably, macular hole
formation in MacTel type 2 may show a minor temporal
displacement from the foveal center. In one report, vitreor-
etinal surgery for two eyes with a full thickness macular hole
did not result in closure of the macular hole (Charbel Issa et al.,
2009c). Functional improvement was moderate in one eye (20/
100e20/63) and absent in the other. There were two recent
case reports on a successful closure of a full thickness
macular hole in patients with MacTel type 2 (Gregori and
Flynn, 2010; Shukla, 2011). However, in the second patient re-
ported by Gregori and Flynn, the macular hole reopened after 4
months. Spontaneous closure of a small full thickness macular
hole with a conﬁguration similar to that of an idiopathic
macular hole has been reported (Shukla and Venkatesh, 2012). Neovascular complexes (Fig. 2) as another feature potentially
complicating the natural disease course may develop at any
time point. Frequently (Gass and Blodi, 1993) but not invariably
(Yannuzzi et al., 2006) they are preceded by the presence of
blunted venules and intraretinal pigment plaques temporal to
the foveola. The lesionsmaypresentwith accompanying retinal
edema, yellowexudates and sub- or intraretinal hemorrhage, or
may appear rather ﬁbrotic and inactive with surrounding
pigmentation and accompanying neurosensory atrophy. Neo-
vascular complexes are most commonly located temporally to
the foveola (Engelbrecht et al., 2002). The origin of these lesions
appears to be different from choroidal neovascularization as
observed in age-related macular degeneration. They rather
seem to originate from the retinal vasculature, but may gain
access to the subretinal space and may develop chorio-retinal
shunts in some eyes (Davidorf et al., 2004; Engelbrecht et al.,
2002; Gass and Blodi, 1993). Sometimes the membranes have
the appearance of markedly ectatic capillaries, possibly repre-
senting retinaleretinal anastomosis. There might be an
increased risk for developing disciform ﬁbrotic lesions in the
fellow eye if one eye is already affected (Casswell et al., 1986).
6. Retinal imaging
6.1. Fluorescein angiography
Characteristic ﬁndings on ﬂuorescein angiography (Figs. 1, 2 and
6) are telangiectatic capillaries predominantly temporal to the
foveola in the early phase and a diffuse hyperﬂuorescence in the late
phase. The late hyperﬂuorescence appears to be an earlier sign than
the telangiectatic alterations. Stereoscopic angiographic studies
suggested that the vascular alterations mainly affect the deeper
capillary plexus (Gass and Oyakawa, 1982) and that the late diffuse
ﬂuorescence on ﬂuorescein angiography appears to originate from
the outer retina. Some telangiectatic capillaries do not appear in the
ﬁrst dye transit as would be expected in presence of aneurysmal
structural changes of the macular vasculature. Therefore, focal
staining of the vessel walls, e.g. due to an incompetent endothelial
barrier, may contribute to the telangiectatic vascular appearance on
ﬂuorescein angiography. In addition to the diffuse hyperﬂuorescence
that is due to leakage from affected capillaries, there may be mild
diffuse hyperﬂuorescence in absence of visible ectatic capillaries in
very early disease stages. This was interpreted asmild staining at the
level of the outer retina (Gass and Blodi, 1993), but it may as well at
least in part be due to the recently described loss ofmacular pigment
(see Chapter 6.5) that results in a relative window defect for the
choroidal background ﬂuorescence (Gillies et al., 2009). The deep
localization of diffuse hyperﬂuorescence observed in stereoangio-
graphic studies might furthermore be explained by an effect of VEGF
on the outer retinal barrier (Ablonczy and Crosson, 2007) or by the
thinning or loss of outer retinal tissue resulting in apparent deep
localization of vascular leakage. The hyporeﬂective cavities that are
bestvisibleonOCT imaging typicallydonot showﬂuoresceinpooling.
Gass and Blodi (1993) reported that in stages 1e4, the late
angiographic leakage usually spares the center of the fovea, with the
exception of few eyes that showed angiographic evidence of capil-
lary ingrowth into the foveal avascular zone in the absence of neo-
vascularisation. However, the diffuse late phase hyperﬂuorescence
mayalso spread to the foveal center in absence of capillary ingrowth
but with very profound leakage. Angiographically visible para-
central alterations are usually conﬁned to an area within one disc
diameter eccentricity from the foveal center and virtually always
involve the temporal sector. In 182 analyzed eyes, paracentral
angiographic leakage was found to involve 90e180 in 112 eyes
(62%), 180e270 17 eyes (9%) and greater than 270, i.e. all four
Table 3
Findings on OCT imaging in patients with macular telangiectasia type 2.
Optical coherence tomography
Hyporeﬂective cavities of the inner and
outer neurosensory retina
Frequent
Normal or subnormal retinal thickness
despite angiographic leakage
Frequent
Disruption of the border between inner
and outer photoreceptor segments
Frequent
Increased reﬂectivity of inner neurosensory
layers
Frequent
Hyperreﬂective intra- or subretinal lesions
(pigment migration or neovascular
membranes) in late disease stages
Frequent
Outer neurosensory atrophy in late disease stages Frequent
Foveal detachment Rare
Lamellar or full thickness macular holes Rare
Subfoveal debris accumulation Rare
Fig. 2. Neovascular complexes originating from the retinal vasculature may occur at any disease stage. A) Fluorescein (A1) and indocyanine green (A2) angiography of a large
neovascular complex (left: early angiographic frames; middle: late frames). There is some ﬁbrotic appearance (A3) and relatively little intraretinal exudation (A4). The arrow (A2)
marks the arterial feeding vessel and the arrow heads mark draining venules of a neovascular complex. BeD) Active neovascular membrane with foveal hemorrhage (B), early
(C) and late (D) phases of a ﬁbrotic stage with pigmentation. There is remarkably little exudation and no cystoid edema or subretinal ﬂuid. The arrows (D) mark corresponding
positions.
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the angiographic area of leakage generally shows a horizontal oval
conﬁguration.
Fluorescein angiography has been the gold standard to conﬁrm
thediagnosis ofMacTel type2.However, it shouldbepointedout that
retinal changes occur inMacTel type 2 thatmay be separate from the
angiographically visible vascular alterations, and probably precede
them. For instance, the area of increased reﬂectivity on confocal blue
reﬂectance imaging (see Chapter 6.3; Fig. 6), and thus the area of
macular pigment loss, is larger than the region showing late phase
leakage on ﬂuorescein angiography (Charbel Issa et al., 2008a). If the
vascular alterations in MacTel type 2 represent a secondary reaction
to some other primary insult, then phenotyping needs to take into
account imaging modalities other than angiography.
6.2. Optical coherence tomography
Optical coherence tomography (OCT), a non-contact, cross-
sectional in vivo imaging of the retina (Costa et al., 2006), has
become a valuable tool for diagnosing and studying MacTel type 2.
An overview of studies reporting ﬁndings on OCT imaging in
patients withMacTel type 2 is provided in the supplementary table.There are characteristic ﬁndings on OCT imaging (overview in
Table 3) that may present in various combinations. The changes are
usually most prominent temporal to the foveal center. Larger
longitudinal studies exploring the natural history on OCT imaging
are currently lacking. However, based on exemplary case studies,
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niques and functional parameters, a time course of alterations may
be proposed (Fig. 3):
The earliest subtle changes on OCT imaging may include
temporal enlargement of the foveal pit (Fig. 3B), which then
appears asymmetric with its thinnest sector temporal to the
anatomic foveal center (Gillies et al., 2009). This minor structural
alteration appears to be due to changes in the outer nuclear/Henle’s
ﬁber layer thickness. However, if capillary leakage occurs within the
same area, this asymmetric thinning may disappear due to a slight
thickening mainly within the inner retinal layers (Fig. 3C). Such
vascular leakage may be associated with a slightly increased
reﬂectivity of inner neurosensory layers. Alterations of the reﬂec-
tivity at the level of the photoreceptor outer segments may also be
seen early in the course of the disease.
Hyporeﬂective cavities may develop within the inner retina
(Fig. 3DeF) which are usually located in the foveal pit with
a predilection for the temporal slope. These atrophic hyporeﬂectiveFig. 3. Phenotypic ﬁndings on spectral domain OCT imaging in patients with MacTel type 2.
the foveal center. A) Normal retina. B) An asymmetric foveal contour may occur very early in
may also be an early ﬁnding. DeF) Hyporeﬂective cavities within the inner foveal layers m
reﬂective line above the retinal pigment epithelium and thinning of the outer nuclear layer m
outer retina. H) Collapse of such outer retinal cavities. EeJ) Atrophic outer retina with hyperr
limiting membrane. L) A lamellar macular hole may develop after disruption of the inner li
pigment epithelial proliferation (N).spaces may have the appearance on funduscopy of a lamellar
macular hole (“pseudo-lamellar macular hole”; Fig. 1G). In contrast
to other diseases such as diabetic maculopathy or Irvine-Gass-
Syndrome, there is no angiographic leakage and pooling of ﬂuo-
rescein dye into the hyporeﬂective cavities in MacTel type 2
(Koizumi et al., 2006), and there is no similar neurosensory thick-
ening. The hyporeﬂective cavities in MacTel type 2 were shown to
have a reﬂectivity different from exudative macular cysts
(Barthelmes et al., 2008b). These differences suggest that atrophy,
as may be found in retinal dystrophies, rather than exudation leads
to the formation of these cavities in MacTel type 2. While outer
retinal cavities appear to be due to tissue loss in the photoreceptor
layer (see below), inner hyporeﬂective cavities might also result
from loss of structural integrity with a pathophysiology similar to
that seen in X-linked retinoschisis or retinitis pigmentosa. As well,
detachment of the foveolar neurosensory retina from the inner
limiting membrane may result in a foveal hyporeﬂective cavity and
an apparent ﬂattening of the foveal pit, especially in presence ofThe optic nerve head is always to the left side in each of these horizontal scans through
the disease. C) Hyperreﬂectivity within the inner retinal layers due to capillary leakage
ay remain without marked functional loss. There is some discontinuity of the highly
ainly centrally and temporal to the foveal center. G) Hyporeﬂective cavities within the
eﬂective pigment plaques. JeK) The inner retinal layers appear to detach from the inner
miting membrane. MeN) Localized complete atrophy of the outer retina with reactive
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reﬂective cavities may decrease with disease progression, possibly
due to loss of supporting structures, surrounding atrophy and
sometimes decreasing leakage.
Another sign of the disease on OCT imaging that may occur
relatively early, but which is also observed in later disease stages, is
the disruption of the line commonly attributed to the photore-
ceptor inner segmenteouter segment border. Discontinuity of this
highly reﬂective line usually starts temporal to the foveola and is
one of the most frequent ﬁndings in MacTel type 2 on OCT imaging.
Modeling of 2-dimensional en face views at the level of the inner
segmenteouter segment border from densely recorded B-scans has
been shown to reveal the extent of loss of this structural alteration
(Sallo et al., 2012b). Two examples including en-face views of the
inner retina are provided in Fig. 4.
In few eyes, accumulation of subretinal debris is evident within
the foveal area (Fig. 8EeF). The histopathological correlate was
suggested to be degenerated photoreceptor elements that have
lipofuscin-like autoﬂuorescent properties, possibly explaining
increased foveal autoﬂuorescence and the funduscopic appearance
of a yellowish foveal spot that is apparent in a small subset of eyes
(Cherepanoff et al., 2012).
With disease progression, atrophy of the outer neurosensory
retina, i.e. the photoreceptor layer, becomes increasingly prevalent
(Fig. 3GeN). Possibly depending on the integrity of supporting
structures, outer hyporeﬂective cavitiesmaydevelop (Fig. 3G,H) and
increasewithin the photoreceptor layer, then subsequently collapse
leading to apposition of inner retinal layers onto the pigment
epithelium (Fig. 3JeN). Such apposition often occurs without the
intermediate stage of cavitation of the photoreceptor layer.
Hyper-reﬂective intraretinal lesions (Fig. 3I) are usually associ-
ated with pigment plaques. They may ﬁrst appear as slightlyFig. 4. “En Face”-view of OCT volume-scans. The left image shows the correspondent fundus
line indicates the position of the B-scan shown in the middle and right image. The asterisk m
images are aligned parallel to the inner limiting membrane to show the inner retinal layers. T
band and show the topographic distribution of the disruption of the line representing the
altered reﬂectivity within the inner segmenteouter segment border corresponds to the entir
area centered temporal to the foveola.prominent hyperreﬂective elevation within areas of photoreceptor
atrophy, progressing into the retinal tissue. Larger lesions may
present as a ﬂat hyperreﬂective structure in the inner retinal layer,
masking features of the underlying tissue. Secondary neovascular
complexes may present as a hyperreﬂective lesion on OCT images
(Fig. 2). In these cases the lesion typically is located in or external to
the outer neurosensory retinal layers.
Quantitative analysis showed decreased thickness of the central
neurosensory retina in most studies, likely due to thinning of the
photoreceptor layer (Krivosic et al., 2009). Characteristic retinal
thickness maps are shown in Fig. 5 that highlight asymmetry of the
foveal depression, loss of retinal contour, and a general thinning of
the macular area secondary to outer retinal atrophy. It has been
pointed out that apparent normal or slightly increased macular
thickness may occur due to the low grade macular edema super-
imposed on the atrophic neurosensory retina (Charbel Issa et al.,
2008d; Charbel Issa et al., 2007b). Increased macular thickness
measurements may be found in MacTel type 2 eyes with marked
capillary leakage and only little atrophy, in eyes with foveal
detachment, pronounced pigment proliferation (Gaudric et al.,
2006) or neovascular membranes.
6.3. Confocal reﬂectance imaging
Confocal reﬂectance imaging was suggested to be helpful in the
diagnosis of MacTel type 2 as well as in the differentiation between
early and late disease manifestations (Charbel Issa et al., 2008a;
Charbel Issa et al., 2008b).
Imaging with a blue laser at 488 nm revealed an increased
reﬂectance in the parafoveolar region of eyes with MacTel type 2
(Bottoni et al., 2010; Charbel Issa et al., 2008a; Charbel Issa et al.,
2008b) (Fig. 6). This phenomenon was observed in most eyesautoﬂuorescence, the black box indicating the position of the volume scan. The dotted
arks the foveal center. The arrow marks the position of the en-face image. The middle
here is a round hole centered on the foveola. The right images are aligned along the RPE
inner segmenteouter segment border of the photoreceptors. In patient A, the area of
e retinal area affected by disease, whereas in patient B, this area is more conﬁned to an
Fig. 5. Retinal thickness maps in an age-matched normal control (A) and patients with MacTel type 2 (BeF), representing the phenotypic variability. The B-scan underneath each
thickness map was recorded through the foveal center (marked by an asterisk). Overall, there is an asymmetry of the foveal depression, a loss of retinal contour, and a general
thinning of the macular area. In later disease stages, there is pronounced retinal thinning due to outer retinal atrophy.
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invasive technique may be diagnostically useful. The area of
increased blue reﬂectance is usually slightly larger than the area of
hyperﬂuorescence in late-phase ﬂuorescein angiography (Fig. 6),
providing evidence for a disease process that goes beyond the
margins of the angiographically visible vascular alterations.
Interestingly, the involved area was topographically related to
areas of macular pigment depletion (see Chapter 6.4) (Charbel Issa
et al., 2008a). Since macular pigment has an absorption maximum
near 488 nm, its reduction would lead to decreased absorption
and thus increased reﬂection of blue light. Increased light scatter
due to the structural alterations of the neurosensory retina may
possibly also contribute to the observed increase in reﬂectivity, but
should not play a major role when using a confocal imaging
system. There appear to be further factors that inﬂuence the
appearance of confocal blue reﬂectance images: although loss of
macular pigment and structural alterations persist, the increased
reﬂectivity may decline in later stages of the disease. This seems to
start temporal to the foveal center, possibly due to advanced
neurosensory atrophic alterations, and may therefore result in
a (transient) ring-shaped increased reﬂectance observed in some
eyes.
Confocal reﬂectance images using an 820 nm laser light source
may reveal decreased reﬂectance of the affected macular areas of
eyes with progressed retinal alterations. Reduced integrity of
structures with high reﬂectivity in the infrared range may be the
cause of this decreased signal. Such structures include the inner
segmenteouter segment border of the photoreceptor layer which
exhibits marked alterations in patients with MacTel type 2 (see
Chapter 6.2). However, the ability of this technique to differen-
tiate eyes with late from those with early disease stages has not
been validated in larger studies, and other alterations affecting
retinal reﬂectivity may be superimposed depending on the
disease stage.6.4. Macular pigment density
Macular pigment, consisting of lutein and zeaxanthin, is
highly accumulated along the axons of the cone photoreceptors
in the central retina (Davies and Morland, 2004; Snodderly et al.,
1984a, 1984b; Whitehead et al., 2006). A number of functions
have been proposed for macular pigment (Davies and Morland,
2004; Whitehead et al., 2006), including ﬁltration of blue light
which may reduce photic damage and glare, minimize the effects
of chromatic aberration on visual acuity, improve ﬁne detail
discrimination and enhance contrast sensitivity. Its neutraliza-
tion of reactive oxygen species may have a protective effect on
the neurosensory retina. Although there may be a large variation
with regard to the concentration of macular pigment, the pattern
of distribution is relatively uniform in the normal population. It
generally shows a peak concentration at the foveal center,
rapidly decreasing with eccentricity and with very little at
eccentricities 8.
Since confocal blue reﬂectance imaging had suggested a focal
loss of macular pigment in MacTel type 2 (Charbel Issa et al.,
2008a), this was further investigated using various techniques,
including two-wavelength fundus autoﬂuorescence (AF), two-
wavelength reﬂectance maps, spectral fundus reﬂectometry and
heterochromatic ﬂicker photometry (Charbel Issa et al., 2009d;
Helb et al., 2008). With the exception of heterochromatic ﬂicker
photometry (representing an inadequate method in this disease
because it assumes the highest macular pigment density centrally),
all other analyses conﬁrmed that macular pigment density is
reduced in MacTel type 2 following a characteristic pattern. This
includes a loss of macular pigment conﬁned to or most pronounced
in the area temporal to the foveal center, and no loss of macular
pigment at an eccentricity of about6.5 in the horizontal axis and
5 in the vertical axis (Charbel Issa et al., 2009d; Helb et al., 2008).
Quantitative analysis conﬁrmed that the loss of macular pigment
Fig. 6. Confocal blue reﬂectance imaging (left) shows a highly reﬂective oval areas that correspond to loss of blue light-absorbing lutein and zeaxanthin on macular pigment maps
(middle). Fluorescein angiography reveals leakage within a smaller area than that of macular pigment loss. The white line delineates the area of increased blue reﬂectance. Examples
of three individual patients are shown (AeC). A representative normal confocal blue reﬂectance image can be found in Charbel Issa et al., 2008a, Fig. 1A. A representative normal
macular pigment distribution is shown in Fig. 7B.
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parafoveolar area and suggested that zeaxanthin would be more
reduced than lutein (Charbel Issa et al., 2009d). A trend towards
a higher macular pigment density just eccentric to the central loss
of macular pigment would require further analysis. Fig. 7 provides
an overview on the range of macular pigment loss observed in
patients with MacTel type 2.
Additional conclusive proof for the central loss of macular
pigment comes from a post mortemmacroscopic photograph of the
eye cup from a patient suffering fromMacTel Type 2 (Powner et al.,
2010). Instead of the usual central yellow spot, there was a yellow
ring of macular pigment at the same eccentricity where it would be
expected from the in vivo imaging studies (Fig. 7H).
The loss of macular pigment has later been divided into 3 classes
based on a cross sectional analysis of two-wavelengths fundus AF
images (Zeimer et al., 2010b). Accordingly, class 1 shows a wedge-
shaped loss of macular pigment restricted to an area temporal to
the foveal center. In class 2, the area enlarges and also involves the
foveal center. Class 3 is characterized by loss of macular pigment
within an oval shaped area centered on the foveola. There was
a signiﬁcant association of the consecutive 3 classes of macular
pigment loss with consecutive disease stages according to Gass and
Blodi. Future longitudinal studiesmay reveal if such classiﬁcation of
loss of macular pigment indeed represents consecutive disease
stages or if different phenotypic sub-forms are involved.Two patients who had lutein and zeaxanthin supplementation
for several years showed higher than average macular pigment
density outside the area of most pronounced macular pigment loss
(Charbel Issa et al., 2009d). This suggested that accumulation of
lutein and zeaxanthin may still be possible, although not in areas
most affected by macular pigment depletion. In an interventional
pilot study in 11 patients, Zeimer et al. further addressed the
question if restoration of macular pigment density would be
possible in patients with MacTel type 2 (Zeimer et al., 2010a). Oral
supplementation of 12 mg lutein and 0.6 mg zeaxanthin for 9
months resulted in an increase of macular pigment only in areas
where the macular pigment was present at baseline. Depletion of
macular pigment at baseline could not be restored. It is therefore
conceivable that degenerative processes inMacTel Type 2 lead to an
impairment in transport and storage of lutein and zeaxanthin so
that those carotenoids may simply be a marker of disease or,
alternatively, may have a role themselves in the disease
pathogenesis.
6.5. Fundus autoﬂuorescence
Short-wavelength fundus AF using blue or green light for exci-
tation has become in recent years a standard technique in clinical
and research settings to investigate and monitor retinal disease.
The short-wavelength AF signal is mainly derived from lipofuscin in
Fig. 7. Macular pigment distribution in a normal eye (B) and at various stages in eyes with MacTel type 2 (CeG). Macular pigment loss may be very subtle only affecting a wedge-
shaped area temporal to the foveal center (C,D), may encompass a larger area with some degree of central/nasal sparing, or may encompass an oval area centered on the fovea. The
post-mortem photographs show the normal macular pigment distribution with the highest peak centrally in an unaffected eye (A) and the ring like distribution with central loss of
macular pigment in an eye with MacTel type 2 (H). The post-mortem photographs (A,H) were kindly provided by Dr. Gregory Hageman.
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depends on additional variables, including the presence and
amount of absorbing pigments or structures.
Macular pigment (absorption maximum: 460 nm) strongly
absorbs blue light. Therefore, fundus AF images recorded after
excitation with a 488 nm (blue light) laser show a strong depen-
dency on macular pigment density and distribution. Consequently,
normal eyes show a central foveal masking on 488 nm fundus AF
images due to the central accumulation of macular pigment
(Fig. 8A). Reducedmacular pigment density or and/or changes in its
topographic distribution in MacTel type 2 may affect this masking.
Indeed, loss of the normal central attenuation of fundus AF is
present in most eyes with MacTel type 2 when blue light is used for
excitation (Fig. 8B,C). This effect is virtually absent when green
excitation light (e.g. a 514 nm laser) is used because of its less
signiﬁcant absorbance by macular pigment.
There appear to be additional patterns of fundus AF alteration in
MacTel type 2 (Fig. 8DeH) that are not explained by loss of macular
pigment which, however, have not yet been studied systematically.
Unbleached photoreceptor pigment has a similar, although lesser,
effect on the appearance of short-wavelength fundus AF as macular
pigment, as it also absorbs and therefore attenuates the excitation
light available to elicit autoﬂuorescence at the level of the pigment
epithelium (Theelen et al., 2008). In the absence of retinal pigment
epithelium atrophy, areas of photoreceptor atrophy (and therefore
reduced photoreceptor pigment density) consequently show
increased AF levels relative to surrounding areas with healthy
photoreceptors (Fig. 8D). Bleaching of photopigment results in
a shift of the spectral absorption maximum towards shorter
wavelengths and therefore less absorption of blue (or green) exci-
tation light (Theelen et al., 2008). Accordingly, photopigment
bleaching decreases the difference in AF intensity between areas
with and without photoreceptor loss. Hyporeﬂective cavities in the
neurosensory retina are also associated with an increased AF
signal; this may also be explained by reduced absorption of the
excitation light by photoreceptors and/or macular pigment (Bottoni
et al., 2010).A further but rare alteration on fundus AF imaging in patients
with MacTel type 2 is a focally increased foveal signal with a yellow
foveal spot as funduscopic correlate (Fig. 8E,F; see also Chapter 5).
This phenomenon is different from other fundus AF abnormalities
in the sense that it is usually not decentered temporally. It neither
disappears with photopigment bleaching, nor is its area correlated
to loss of macular pigment. The pathophysiological correlate might
be an increased accumulation of ﬂuorophores, e.g. lipofuscin or
shed photoreceptor outer segments persisting in the sub-
neurosensory space (Fig. 8E, F).
A focally decreased fundus AF signal is usually due to blockage
(i.e. strong absorption) of the excitation light by advanced retinal
alterations, such as pigment-hypertrophy (Fig. 8H) or neovascular
complexes. Furthermore, atrophy of the retinal pigment epithelium
results in loss of the major ﬂuorophores contributing to the AF
signal, but this may only rarely be the cause for decreased fundus
AF in MacTel type 2.
6.6. Adaptive optics imaging
In adaptive optics imaging, optical aberrations of the eye are
reduced by compensating for distortions that are measured using
wavefront analysis. Combining adaptive optics with e.g. a scanning
laser ophthalmoscope allows the investigation of the photore-
ceptor cone mosaic in vivo (Roorda et al., 2002). Ooto et al. iden-
tiﬁed a lower paracentral cone density in patients with MacTel type
2 compared to normals using this technique (Ooto et al., 2011).
There were also paracentral regions with cone loss, including areas
that showed no leakage on ﬂuorescein angiography.
7. Functional alterations
7.1. Vision-related quality of life
The vision-targeted health-related quality of life, measuredwith
the National Eye Institute Visual Functioning Questionnaire (NEI-
VFQ-25), has been analyzed in the study cohort of the MacTel
Fig. 8. Fundus autoﬂuorescence (AF; excitation at 488 nm) imaging in MacTel type 2. AF imaging may reveal increased signals (BeG) compared to normal (A) for various reasons.
B,C) Where macular pigment (lower images) is decreased, there is usually a lack of the normal foveal masking of the AF signal (upper image) by macular pigment, which absorbs the
blue excitation light. D) Another reason for an increased AF signal in MacTel type 2 may be the loss of photoreceptors and therefore less absorption of the excitation light by
photopigment. Unbleached photopigment in the surrounding area absorbs blue light and therefore decreases the AF signal (left). OCT conﬁrms atrophy of the photoreceptor layer
(marked by vertical bars). After bleaching the photopigment with the excitation light for 1 min, the contrast between areas of preserved and those with lost photopigment
decreases; compare the upper (before bleaching) and lower (after bleaching) images of the middle panel. In this case, bleaching of the surrounding photopigment reduces the
contrast between the area of preserved photoreceptors and the area of photoreceptor loss. Note the different area of macular pigment loss (right) in the same eye. E) The same
recordings as in D), but in an eye where the increased signal is not due to loss of macular pigment or photoreceptors, but rather appears to originate from additional subfoveal
ﬂuorophores. F) A similar phenomenon as in E), but more pronounced (same patient as in Fig. 1E with strong ﬂuorescence of the yellow spot). G) Increased AF due to a full thickness
macular hole. H) A decreased fundus AF signal due to blockage by pigment plaques (same patient as in Fig. 1H).
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lower vision-related functioning in most measured subscales
(except color vision) compared to a reference group with macular
degeneration that had the same level of central visual acuity.
Therefore, functional outcome measures different from distance
visual acuity testing appear to be necessary to fully evaluate the
functional deﬁcits in MacTel type 2. This may include central visual
ﬁeld testing to identify characteristic paracentral scotomata (e.g. by
microperimetry) or assessment of reading ability (both see below).
A similar conclusion may be drawn from a study that investi-
gated the longitudinal impact of MacTel type 2 on vision-related
quality of life using the Impact of Vision Impairment (IVI) ques-
tionnaire (Lamoureux et al., 2011). At baseline, there was a lower
level of vision-speciﬁc quality of life in a subset of 22MacTel type 2
patients compared with controls. Items associated with reading
were identiﬁed as being most difﬁcult. There was no change in
distance visual acuity and no change in any of the IVI question-
naire scores at the 24 months follow up. However, other param-
eters of visual function were not included. Therefore, currently
available quality of life studies may not fully reveal the impact of
increasing functional defects that are characteristic and poten-
tially sensitive for MacTel type 2 (e.g. central visual ﬁeld testing,
reading ability).
7.2. Visual acuity
Functional impairment may be mild with no or only slight
reduction in binocular best-corrected visual acuity in the early
stages of MacTel type 2. However, loss of visual acuity in at least one
eye is a frequently reported complaint (Gass and Blodi, 1993).
Notably, even in the presence of deep paracentral scotomata and
reduced reading ability, distance visual acuity may be relatively
preserved (Charbel Issa et al., 2007a; Finger et al., 2009). However,
a decrease in visual acuity may eventually occur with disease
progression. There appear to be essentially two different factors
contributing to the decline of visual acuity (Charbel Issa et al., 2011).
Initially, there may be a slow drop in visual acuity usually not
beloww20/50 which may be due to structural foveal changes, e.g.
a low-grade chronic vascular leakage or hyporeﬂective cavities in
the inner retina. The second andmore important factor for a decline
in visual acuity is atrophy of the foveal photoreceptors which may
result in eccentric ﬁxation and a visual acuity of around 20/200.
Such photoreceptor dropout initially occurs temporal to the foveola
causing the characteristic deep paracentral scotomata (see Chapter
7.3) and may later spread centrally. If a relatively faster drop in
visual acuity is observed, an associatedmacular hole or neovascular
complex may be suspected. Visual acuity below 20/200 is rarely
observed but there may be marked functional impairment in very
late disease stages with large central areas of photoreceptor
atrophy or due to the development of a larger neovascular complex
(Engelbrecht et al., 2002; Gass and Blodi, 1993; Watzke et al., 2005;
Yannuzzi et al., 2006).
Analysis of the baseline characteristics of patients enrolled in
the MacTel study revealed a mean visual acuity of 20/40 in 522
untreated eyes (better eye 20/32, worse eye 20/50) (Clemons
et al., 2010). Visual acuity was 20/20 or better in 16%, and
approximately half of the eyes had 20/32 or better vision. Visual
acuity was worse than 20/50 in the better eye in only 14%. Char-
acteristics for later disease stages such as pigment-hyperplasia or
blunted venules were associated with a lower visual acuity
(Clemons et al., 2010).
Similar results were found in the cohort reported by Gass and
Blodi (1993): visual acuity was 20/20 or better in 32 (18%) of 182
eyes and median visual acuity was 20/40 (range 20/15 to hand
motions). No patient had a visual acuity of 20/200 or worse in botheyes (Gass and Blodi, 1993). They stated that most patients would
become symptomatic only after occurrence of stage 3 changes (see
Chapter 8) and somemaintained good visual acuity even after stage
4 changes had developed. Of their 92 patients, 72 were followed for
at least 2 years with a mean follow up time of 91 months (range
24e316 months). The ﬁnal visual acuity was 20/30 or better in at
least one eye of 27 patients. In the 37 eyes with 20/200 or less visual
acuity, the primary cause was foveal atrophy in 26 eyes, neo-
vascular complex 10 eyes, and cataract in 1 eye. Ten patients were
legally blind at the last follow-up.
Watzke and co-workers reported that visual acuity may decline
gradually but, overall, 25% of eyes (6 out of 24) remained stable
during a review period of 10e17 years (Watzke et al., 2005).
Engelbrecht et al. retrospectively studied the natural visual
outcome in 26 eyes that developed stage 5 disease (Engelbrecht
et al., 2002); 80% of these eyes had a ﬁnal visual acuity of 20/100
or worse.
7.3. Central visual ﬁeld
Metamorphopsia or a positive scotoma in patients with MacTel
type 2 was noted in earlier case series (Abujamra et al., 2000; Gass
and Oyakawa, 1982). To explore further the presence of scotomata,
we used fundus-controlled perimetry (microperimetry) to record
functional deﬁcits with high resolution (Charbel Issa et al., 2007a)
(Fig. 9). Early disease stages (stages 1 and 2; see Chapter 8) usually
showed preserved retinal sensitivity. In later stages, paracentral
sensitivity declined showing the main defects at about 2 eccen-
tricity temporal and temporal inferior to the foveal center.
Depending on the presence and extent of photoreceptor atrophy,
such deep scotomatamay ormay not be present in stage 3. In stages
4 and 5, absolute scotomata can almost always be detected, usually
topographically related to retinal pigment hyperplasia or neo-
vascularisation on funduscopy which both are associated with
atrophy of the photoreceptor layer on OCT imaging (Charbel Issa
et al., 2007a). Although it may initially be difﬁcult to detect the
small and localized scotomata, they may enlarge due to progressive
photoreceptor atrophy. This may eventually lead to a central
scotoma involving the foveal center and paracentral areas possibly
as large as the angiographically visible affected area. Detection of
the paracentral scotomata revealed by microperimetry was poor
using the Amsler grid (Charbel Issa et al., 2009b). This is likely due
to perceptual completion of small functional defects, which
consists of a ﬁlling-in of the missing information when part of an
image falls on a blind area of the visual ﬁeld (Gerrits and
Timmerman, 1969).
Visual acuity was correlated with the central foveal light
sensitivity but not with the paracentral light sensitivity temporally
(Charbel Issa et al., 2007a), suggesting that microperimetry would
indeed add information on the functional alterations inMacTel type
2. This assumption was supported by a recent analysis of longitu-
dinal data from an interventional study that showed no change in
visual acuity but a decrease in paracentral light sensitivity on
microperimetry (Charbel Issa et al., 2010).
Fine matrix mapping to study the scotopic function within the
central visual ﬁeld revealed an earlier decrease and more severe
affection of scotopic rod compared to photopic cone function
(Schmitz-Valckenberg et al., 2008). A subsequent longitudinal
observation of nine eyes over one year suggested a superior
sensitivity of scotopic ﬁne matrix mapping to monitor progression
of the functional deﬁcit compared with microperimetry (Schmitz-
Valckenberg et al., 2009). Assessment of scotopic macular func-
tion using ﬁne matrix mapping is, however, time consuming and
not widely available. Therefore, it may not be suitable for larger
patient cohorts in clinical trials.
Fig. 9. Microperimetry in 3 different patients (rows AeC) with MacTel type 2 over a 4-year-follow up. Absolute scotoma temporal to the fovea (deep red color) progresses
considerably, whereas visual acuity (VA) remains largely stable.
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defects, and perimetry of the retinal periphery has not been
systematically performed.
7.4. Reading ability
Efﬁcient reading requires not only sufﬁcient visual acuity to
resolve the letters, but also a sufﬁcient extent of central visual ﬁeld
of usually at least 4 to sufﬁciently process words and to perform
adequate eye movements (Trauzettel-Klosinski, 2002). It was
therefore hypothesized that the characteristic paracentral scoto-
mata could impair the reading ability of patients with MacTel type
2. Indeed, these patients exhibit a signiﬁcantly reduced monocular
reading acuity (mean 20/63) and considerably reduced reading
speed to almost 50 words per minute compared with an average
of 190 words per minute in the control group (Finger et al., 2009).
Regression analysis showed that a reduction in distance visual
acuity and the characteristic temporal scotomata were signiﬁcant
predictors for both variables of reading performance (reading
speed and reading acuity). The ﬁxation stability was not signiﬁ-
cantly different from controls (Finger et al., 2009). Accordingly,
these ﬁndings indicated that paracentral sensitivity loss in MacTel
type 2 is associated with loss of reading performance despite
stable central ﬁxation. Since it has been shown in several studies
of other retinal diseases that reading ability is strongly associatedwith quality of life, therapeutic intervention in MacTel type 2
should be aimed at maintaining patients’ reading ability (Finger
et al., 2009).7.5. Metamorphopsia
Metamorphopsia has been rarely investigated in retinal diseases
in a systematic way, most likely due to the scarcity of standardized
and validated tests that would allow its quantiﬁcation. We
showed that in the majority (83%, n ¼ 36) of eyes without neo-
vascularization perception of distortions could be detected with the
Amsler grid (Charbel Issa et al., 2009b). If present, metamorphopsia
was always detected in the nasal quadrant of the central visual ﬁeld,
and were strongest in the nasal and upper quadrant of the testing
grid. This localization of metamorphopsia is consistent with the
predominant disease manifestation temporal/temporal inferior to
the foveal center. The degree of distortions often but not always
correlated with the degree of angiographically visible leakage.
Metamorphopsia was also present in eyes with earlier disease that
showed no scotoma on microperimetry testing and thus appears to
be an early symptom in MacTel type 2. A quantitative analysis of
metamorphopsia, e.g. using m-charts (Matsumoto et al., 2003), as
well as correlations with other vision related tasks has not yet been
performed.
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Gass and Oyakawa reported the ﬁrst electrophysiologic studies
in three patients with MacTel type 2 (Gass and Oyakawa, 1982).
Electrooculography and full-ﬁeld electroretinography were found
to be normal. However, a recent case report presented a patient
with features of cone dystrophy with signiﬁcantly reduced cone-
driven responses on electroretinography (Barthelmes et al., 2007).
Three years later, the patient had developed features typical for
MacTel type 2 including vascular alterations on ﬂuorescein angi-
ography. Larger studies including multifocal electroretinography
will be necessary to further elucidate electrophysiologically
measurable deﬁcits in MacTel type 2.
8. Structureefunction correlation
Since microperimetry seems to be most appropriate for
measuring functional deﬁcits in patientswithMacTel type 2, several
studies have been reported on the structureefunction correlation
based on microperimetry data (Charbel Issa et al., 2008d; Charbel
Issa et al., 2007a; Charbel Issa et al., 2010; Maruko et al., 2008;
Schmitz-Valckenberg et al., 2008, 2009; Wong et al., 2009). If no
marked atrophic alterations are present, there appears to be no
correlation between retinal thickness and retinal sensitivity
(Charbel Issa et al., 2008d). Thus, it was concluded that qualitative
assessment of the retinal structure would be more meaningful than
retinal thickness analysis. Such cross sectional qualitative analysis
revealed that marked defects in retinal sensitivity are correlated
with outer retinal atrophy on OCT imaging and with pigment-
hypertrophy on fundus photography (Charbel Issa et al., 2007a;
Maruko et al., 2008; Schmitz-Valckenberg et al., 2008; Wong et al.,
2009). However, those studies showed no point-to-point correla-
tion and included only small patient numbers. A subsequent high-
resolution structureefunction correlation conﬁrmed the impor-
tance of outer retinal alterations for functional loss.While structural
damage to the outer retina (photoreceptor layers)was accompanied
by a loss of retinal sensitivity as detected by microperimetry,
structural changes limited to the inner retina typically showed
preserved function (Charbel Issa et al., 2010). The same study
revealed that there appears to be an association of retinal function
with the photoreceptor layer thickness (Charbel Issa et al., 2010).
Conclusions on retinal function based on total retinal thickness
measurements may be less valid due to low grade retinal edema,
pigmentmigrationor neovascular complexes that allmayadd to this
thickness parameter (Charbel Issa et al., 2008d). Microperimetry
data was also overlaid with en face OCT-images at the level of the
inner segmenteouter segment border. This study revealed an
association between discontinuity within this OCT-feature and
reduced retinal sensitivity (Sallo et al., 2012b). Zeimer et al. inves-
tigated the possible correlation of macular pigment loss with
microperimetry data (Zeimer et al., 2010b) and found a trend
towards worse retinal function with increasing class of macular
pigment changes (see Chapter 6.4). Correlations with disease char-
acteristics on fundus AF imaging (Wong et al., 2009) should be
considered carefully due to the variable functional impact of the
different fundus AF phenomena (see Chapter 6.6).
Distance visual acuity has been correlated with structural
alterations from baseline data of the MacTel Natural History
study cohort (Clemons et al., 2010). The presence of pigment-
hypertrophy as well as of blunted venules showed the most
signiﬁcant association with decreased visual acuity. Characteristic
fundus AF patterns, especially when involving the foveal center, as
well as disease speciﬁc (but not further divided) OCT character-
istics also revealed a signiﬁcant association with visual acuity.
Gaudric et al. (2006) pointed out that the frequently observeddisruption of the photoreceptor inner segmenteouter segment
border (see Chapter 6.2) does not necessarily mean photoreceptor
loss, since function may still be retained. The authors suggested
that the signal of this highly reﬂective line might be impaired by
a change in the spatial orientation of the photoreceptor outer
segments or by any other change in their structure. Accordant,
foveal center involvement of the area with loss of the inner
segmenteouter segment border showed no signiﬁcant correlation
with visual acuity (Sallo et al., 2012b). Ooto et al. found a correla-
tion of cone density with the integrity of the border between inner
and outer photoreceptor segments and with visual acuity using
adaptive optics (Ooto et al., 2011). As mentioned in Chapter 7.2,
photoreceptor atrophy of the foveal center might be the most
important factor determining distance visual acuity; however, this
has not yet been investigated in detail. The pattern of macular
pigment loss appears to have some correlation with distance
visual acuity (Zeimer et al., 2010b). There was signiﬁcantly better
visual acuity in eyes with macular pigment alterations consistent
with class 1 compared with those with a loss of central macular
pigment density (class 2 and 3; see Chapter 6.4).
Overall, it appears that spectral domain OCTstudieswith a dense
B-scan rastermaybeapromising surrogate forassessmentofdisease
progression in MacTel type 2 (Charbel Issa et al., 2010). This may be
achieved either byanalyzing B-scans individually (Charbel Issa et al.,
2010) or by using those data to construct en face views at deﬁned
retinal layers (Sallo et al., 2012b). However, strong evidence still
needs to be provided for such surrogatemarkers. For disease staging
and measurement or prediction of progression, other parameters,
including macular pigment distribution, funduscopic ﬁndings or
angiographic disease activity, may also need to be considered.
9. Disease staging
There appears to be a chronological appearance of the various
fundus changes. Of note, subtle macular alterations may be detec-
ted on clinical fundus exam but may be missed on fundus photo-
graphs analyzed in studies, leading to a possible underestimation of
the true frequency of certain ﬁndings (Table 2). Generally, the ﬁrst
visible alterations appear at the foveola (changes of foveolar reﬂex,
pseudo-lamellar macular hole) and temporal to the foveola (retinal
graying). The disease may later spread to encompass the entire oval
macular area with the most pronounced alterations temporally
(Davidorf et al., 2004). With progressing photoreceptor atrophy,
ectatic capillaries and retinal graying may disappear, and this again
usually ﬁrst occurs in the temporal parafoveolar quadrants. In
a subset of patients, the asymmetry within one eye may be very
pronounced, so that nasal paracentral macular areas may appear
normal while marked atrophy is present temporal to the foveola.
Gass and Blodi suggested a temporal sequence of 5 disease
stages (Table 1) based on a retrospective analysis of fundus
photography and ﬂuorescein angiographic ﬁndings (Gass and Blodi,
1993), without the currently available technology, including fundus
autoﬂuorescence, optical coherence tomography (OCT) and
microperimetry. According to their system, stage 1 is characterized
by only mild hyperﬂuorescence on angiography, usually temporal
to the foveola. In stage 2, there is a slight graying of the parafoveolar
retina and minimal or no visible telangiectatic vessels. Stage 3 is
characterized by dilated right angled vessels that may be both
venular and arteriolar in nature and stage 4 by intraretinal prolif-
eration of pigment epithelial cells typically along right angled
vessels. Stage 5 is characterized by secondary neovascularization.
Longitudinal observations of serial photographs (64 eyes of 32
patients, follow up of 2 years or longer) revealed the development
of new pigment plaques in 20 eyes, a new neovascular complex in 7
eyes, new superﬁcial crystalline deposits in 5 eyes, the appearance
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a lamellar macular hole in 3 eyes (Gass and Blodi, 1993).
Using the classiﬁcation as suggested by Gass and Blodi, a low
inter-observer reliability for stages 1e3 was reported (Charbel Issa
et al., 2007a). A deep and circumscribed paracentral scotoma, the
characteristic functional loss in MacTel type 2 (see Chapter 6.2), is
always found in stage 4 but may or may not be present in stage 3,
depending on atrophic alterations in the photoreceptor layer
(Charbel Issa et al., 2007a). Neovascular complexes do not strictly
occur in the proposed disease sequence, i.e. as the last stage of the
disease. Similar to macular holes, which may develop due to
a disease-related decreased stability of the foveal structure,
development of neovascular complexes may occur at any time
during the course of the disease. Thus, a suggested classiﬁcation
that divides the condition into non-proliferative and proliferative
(i.e. eyes with neovascular membranes) stages (Yannuzzi et al.,
2006) may be misleading. The natural endpoint of the disease,
localized atrophy of the photoreceptor layer, is not considered in
this classiﬁcation.
In conclusion, the disease staging according to Gass and Blodi
still appears to be the best staging system, with a chronological
sequence of the biomicroscopically visible features essentially in
line with clinical experience. However, their staging does not take
into account the recent advances revealed by novel imaging tech-
niques. Longitudinal data including disease characteristics that
have only become apparent with the advent of new technology,
such as the development of paracentral scotomata caused by focal
photoreceptor death and the loss of macular pigment, need to be
taken into account to develop a more accurate description of
disease staging and progression.
10. Additional associated ocular ﬁndings and systemic
diseases
Based on an analysis in 55 patients and 170 controls, a generally
wider arteriolar and venular calibre outside the macular area was
reported in patients with MacTel type 2 (Tikellis et al., 2009). The
authors suggested that such generalized changes in retinal vascular
calibre might reﬂect an underlying dysfunction of retinal pericytes
or glial cells, and might provide a means to monitor progression of
disease. An alternative possible explanation would be that the
vascular calibre widens due to an increased blood ﬂow within the
macular area.
A smaller foveal avascular zone compared to normal has been
reported in patient with idiopathic juxtafoveolar telangiectasia
(Mansour and Schachat, 1993); however, the proportion of patients
withMacTel type 2 in this study remains unclear and it appears that
mainly other disease entities had been analyzed. Another study
described two cases with a centripetal retinal capillary proliferation
(Koizumi et al., 2007a). From clinical experience, synchisis sci-
nitllans and small hard drusenwith an associatedwindowdefect on
ﬂuorescein angiography (similar to basal laminar drusen) might be
more common inMacTel type 2 patients. Both possible associations
have been reported (Charbel Issa et al., 2007c; Margalit et al., 2002),
but have not been validated in a larger patient group. Co-occurrence
of such ocular ﬁndingsmay be part of the phenotype of MacTel type
2 ormay have been found due to co-existence by chance, depending
of the strength of association that would need to be assessed in
larger patient cohorts. So far, no data is available regarding refrac-
tion or lens status. Notably, an increase of vascular leakage was
observed after cataract surgery (Toy et al., 2012), pointing to
a possible effect of confounding factors on disease activity.
With regards to potential associations with systemic diseases,
baseline analysis of the MacTel study cohort revealed a high prev-
alence of a history of diabetes mellitus (28%) and hypertension(52%). 41% were overweight (body mass index  25) and 43% were
obese (body mass index  30). 12% were current and 38% former
smokers (Clemons et al., 2010). However, there may be sampling
(ascertainment) bias. Also, diabetes mellitus and hypertension
could lead to increased vulnerability of the macular vasculature for
the eponymous vascular alterations. It had been proposed already
in earlier studies that diabetes mellitus may be associated with the
disease (Chew et al., 1986; Millay et al., 1986). However, others
suggested that the associationwould not be stronger than expected
in an agematched population (Maberley et al., 1999; Yannuzzi et al.,
2006). In the study by Gass and Blodi, only one patient had
borderline diabetes and six patients (8%) developed diabetes within
a mean follow up period of 91 months (Gass and Blodi, 1993).
Many other ocular (Bakke andDrolsum, 2006; Gass andOyakawa,
1982; Querques et al., 2010) and systemic (Abujamra et al., 2000;
Fitzsimons et al., 1987; Gass and Blodi, 1993; Gurwin et al., 1985; Lee
et al., 2004; Leys et al., 2000; Parodi et al., 2006; Yannuzzi et al., 2006)
associated diseases have been reported. However, these often were
only single observations and certainly could represent the normal
prevalence in the population and thus coincidence.
11. Histology
Green et al. published a light and electron microscopic study of
an eye with conﬁrmed MacTel type 2 (Green et al., 1980). Notably,
they did not ﬁnd telangiectatic vessels within themacular area. They
reported narrowing of the capillary lumen from proliferation of
amultilaminated endothelial cell basementmembrane, a partial loss
of pericytes, accumulation of lipids within the capillary walls and
localized areas with disrupted endothelial cells. The neurosensory
retina showed intracellular and intercellular edema in the temporal
paracentral area with granular material in the extracellular spaces.
Some ganglion cells and cells in the inner nuclear layer appeared to
be undergoing degeneration. The outer nuclear layer was less
affected and the retinal pigment epithelium appeared normal. They
postulated that the angiographic appearance of telangiectasis could
be due to rapid diffusion of the dye into the thickened wall of the
capillary sites of endothelial cell degeneration, subsequent diffusion
within the wall and eventual leakage into the surrounding tissue. It
should be noted that data on the normal appearance of the aged
human retinal vasculature on electron microscopy is scarce. Green
et al. did not contrast their ﬁndings to an age matched control and
moreover found similar changes as described for the macular area in
the retinal periphery. Notably, Powner et al. have recently identiﬁed
similar alterations in normal eyes from donors of similar age as the
patient reported by Green et al., further suggesting that caution
should be exercised in the interpretation of histopathological case
studies without controls (Powner et al., 2011).
In a separate study, Powner et al. used immunohistological
techniques to assess a donor eye with a well documented diagnosis
of MacTel type 2. An angiogram 12 years before the patient’s death
showed alterations characteristic for MacTel type 2. Striking loss of
central macular pigment was evident macroscopically (see Chapter
6.5). Histology revealed abnormally dilated vessels in the deeper
plexus of the retinal paracentral vasculature. Immunohistochem-
istry suggested a marked reduction of basement membrane
proteins indicating vascular pathology. Claudin-5, a marker for
tight junctions between retinal endothelial cells, showed immu-
noreactivity in normal as well as in telangiectatic vessels. Most
notable was a lack of reactivity to Müller cell markers (including
vimentin and glutamine synthetase) within the area of macular
pigment loss, most likely due to loss or disease of Müller cells. Due
to poor preservation of the photoreceptors in the available sections,
no deﬁnite conclusions were possible regarding the extent of
photoreceptor loss. No differences compared with a control eye
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phages using the Iba1 microglia marker and no obvious abnor-
malities were found within the retinal pigment epithelium
(Powner et al., 2011). The Müller cell pathology observed in this
histological specimen was conﬁrmed by a proteomic study of the
fellow eye. It revealed a reduction of proteins involved in the
glycolytic pathway which occurs in Müller cells, and of glial cell
markers in the diseased macula (Len et al., 2012). The fellow eye
was also studied by electron microscopy (Cherepanoff et al., 2012).
The most signiﬁcant ﬁnding was a subretinal accumulation of
degenerate photoreceptor elements within the central retina with
only minimal retinal pigment epithelial reaction and a normal
appearing Bruch’s membrane. There was also a focal loss of the
outer limiting membrane andmild irregularity of the inner limiting
membrane within the central retina.
Davidorf et al. (2004) presented the histopathological ﬁndings
of a surgically excised neovascular complex in a patient with
MacTel type 2. Notably, the vascular membrane originated from the
retinal vessels and no connection to the underlying choriocapillaris
was found.
A further histopathological study of presumed parafoveal
telangiectasis is mentioned for completeness (Eliassi-Rad and
Green, 1999). The authors described histological ﬁndings that
appear not to be compatible with the current concept of MacTel
type 2. There was no clear clinical diagnosis of MacTel type 2 made
before the patient’s death, suggesting a different diagnosis.
12. Differential diagnosis
Several features of MacTel type 2 may be found in other diseases
that should be considered when funduscopic assessment allows no
clear-cut diagnosis. Findings that may be helpful in distinguishing
MacTel type 2 include the temporal predilection of a bilateral disease
process not respecting the horizontal raphe, the characteristic inner
and outer retinal cavities seen on OCT imaging and the loss of
macular pigment visible on fundus AF imaging. Further clues may be
the apparent lack of retinal thickening despite vascular (low grade)
leakage due to underlying retinal atrophy, and more pronounced
visual disturbance (e.g. reading difﬁculties) than expected from
distance visual acuity testing, which is due to characteristic para-
central absolute scotomata in progressed disease stages.
12.1. Macular telangiectasia type 1
MacTel type 1 (see Table 1), also termed “aneurysmal telangi-
ectasia”, mainly occurs unilaterally, affecting predominantly young
males (Abujamra et al., 2000; Casswell et al., 1986; Gass and Blodi,
1993; Gass and Oyakawa,1982; Lowe et al., 1998; Millay et al., 1986;
Watzke et al., 2005; Yannuzzi et al., 2006). It is less prevalent than
MacTel type 2, although this might not be true in all populations
(Lee et al., 2011; Maruko et al., 2012). Little is known of its patho-
physiology and natural history. It may be that the classiﬁcation into
type 1A and 1B represents different stages of the same disease
rather than different disease groups (Gass and Blodi, 1993; Watzke
et al., 2005; Yannuzzi et al., 2006). It has been proposed that the
disease is a developmental disorder which represents a mild
variant of Coats’ syndrome and Leber’s miliary aneurysms (Cahill
et al., 2001; Gass and Blodi, 1993). Disease severity may be asso-
ciated with age of onset, with earlier disease occurrence having the
worse prognosis (Cahill et al., 2001). No clear association with
systemic or other ocular diseases has been identiﬁed.
The characteristic funduscopic ﬁndings of MacTel Type 1 include
visible aneurysmatic dilation of the macular blood vessels, mainly
conﬁned to the temporal region, with surrounding cystoid macular
edema and yellowish exudates (Gass and Blodi, 1993; Yannuzziet al., 2006). The presence of microaneurysms is an important
feature to distinguish MacTel Type 1 against MacTel Type 2, where
microaneurysms are not a characteristic phenotypic feature. Also,
MacTel Type 1 is a unilateral disease, whereas MacTel Type 2 is
bilateral. A serous or exudative detachment of the macula, a cica-
tricial disciform macular lesion and haemorrhages may develop
(Yannuzzi et al., 2006). The vascular changes typically involve an
irregular or oval zone and are centered temporal to the fovea.
Vascular alterations in extramacular areas were reported to occur
in 20%e50% (Casswell et al., 1986; Gass and Blodi, 1993; Gass and
Oyakawa, 1982; Yannuzzi et al., 2006) or were not observed
(Abujamra et al., 2000; Lowe et al., 1998). The different proportions
of peripheral involvement may be due to different deﬁnitions of
peripheral or extramacular location, the restricted availability of
peripheral angiographic images in retrospective case series or
different diagnostic criteria in the respective studies.
Fluorescein angiography typically reveals vascular aneurysmal
widening of the macular vessels in the early phase with diffuse leak
and cystoid edema in the late phase (Gass and Blodi,1993; Yannuzzi
et al., 2006). There may be variable capillary occlusion or loss,
possibly secondary to longstanding neurosensory edema (Gass and
Blodi, 1993; Yannuzzi et al., 2006). On indocyanine green angiog-
raphy, there commonly is staining of the aneurysmal vascular
changes in the late angiographic phase, which is usually not
observed in MacTel type 2. Optical coherence tomography (OCT)
shows cystoid macular edema with retinal thickening (Surguch
et al., 2006; Yannuzzi et al., 2006), a localized neurosensory
detachment may be present (Yannuzzi et al., 2006). The charac-
teristic localized loss of macular pigment within the central retina
as described for MacTel type 2 is not present in type 1; however,
central macular pigment density has been noted to be slightly
decreased compared to normal (Sawa et al., 2012).
Complaints reported by patients with MacTel type 1 include
impaired visual acuity and blurred vision, less frequently meta-
morphopsia or a negative scotoma (Abujamra et al., 2000; Gass and
Oyakawa, 1982). Patients with MacTel type 1 may present with
advanced disease since they usually have one unaffected eye.
Progressive visual impairment is usually associated with an
increase in the extent of telangiectasia, prominent cystoid macular
edema and/or lipid exudates extending into the foveal center. In
a recent structureefunction correlation, disruption of the inner
segmenteouter segment border and cystoid retinal thickening was
found to be associated with reduced retinal function (Takayama
et al., 2012). Patients with type 1B disease usually only report
mild metamorphopsia while visual acuity may be preserved.
Focal laser photocoagulation (direct coagulation of aneurysms)
has been reported to decrease vascular exudation andmay improve
visual acuity in some patients (Chopdar, 1978; Gass, 1968; Gass and
Blodi, 1993; Gass and Oyakawa,1982; Lowe et al., 1998; Millay et al.,
1986). The success of treatment may depend upon the extent of
pre-existing neurosensory damage due to longstanding edema or
lipid exudates extending into the foveola. Repeated treatment may
be necessary.
Single reports showed that intravitreal administration of the
steroid triamcinolone may result in a decrease of the macular
edema associated with MacTel type 1 (Charbel Issa et al., 2007c; Li
et al., 2005). Intravitreal injections of the VEGF-inhibitor bev-
acizumab have also been tried, but these resulted in reduction of
retinal edema and an increase in visual acuity in only few eyes
(Gamulescu et al., 2008; Matsumoto and Yuzawa, 2010; Takayama
et al., 2010). The vascular alterations, which likely are structural
in nature, did not disappear completely with either intravitreal
steroids or VEGF-inhibitors, the effect in most cases being only
temporary with recurrence of macular edema after cessation of
therapy.
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systematically the natural history and potential long-term treat-
ment effects in this rare condition is lacking. Rebound phenomena
following therapy were described after different treatment
approaches and changes of the activity of the disease, including
spontaneous stabilization and even resolution of the macular
edema without treatment have been reported (Gass and Blodi,
1993; Gass and Oyakawa, 1982). Therefore, intervention should be
recommended thoughtfully and weighed against potential risks
and side effects. If central vision is in danger due to threatened
extension of lipid exudates into the foveola, intervention should
seriously be considered.
12.2. Other diseases associated with macular telangiectasia
Telangiectatic vascular alterations within the macular area may
be observed in diabetic retinopathy, radiation retinopathy, branch
retinal vein occlusion or secondary to inﬂammatory ocular disease.
A thorough medical history is essential. Except in small branch
retinal vein occlusions, these diseases usually reveal more wide-
spread and additional fundus changes, including alterations such as
haemorrhages and nerve ﬁber layer infarcts. Exudative cystoid
macular edema commonly accompanies retinal vascular disease.
Branch retinal vein occlusions usually respect the horizontal raphe
and occur distal to an arteriolar-venular crossing. If the vascular
alterations occur secondary to an inﬂammatory disease, further
related ﬁndings such as vitreous cells and/or vascular sheathing
may be present. Little is known about rare types of idiopathic
macular telangiectasia as proposed in Gass and Blodi’s type 3,
which are associatedwith capillary occlusion and systemic diseases
(Gass and Blodi, 1993). Rare syndromic occurrence of macular
telangiectasia may also include patients with dyskeratosis con-
genita (Yannuzzi, 2010) or facioscapulohumeral muscular
dystrophy (Fitzsimons et al., 1987; Gurwin et al., 1985).
12.3. Diseases with similar neurosensory atrophy
Hyporeﬂective cavities of the neurosensory retina observed with
OCT imaging similar to those inMacTel type 2 have been reported in
patients with a variety of inherited retinal dystrophies (Barthelmes
et al., 2008b; Kellner and Kellner, 2009; Mahajan et al., 2009).
Also, the area affected in MacTel type 2 is similar to that involved in
various inherited dystrophies that present with e.g. bull’s eye mac-
ulopathy (Kurz-Levin et al., 2002; Michaelides et al., 2007).
Atrophic alterations on OCT imaging as observed in MacTel type
2 have also been reported in patients with Tamoxifen-Retinopathy
and with SjögreneLarsson-Syndrome, including hyporeﬂective
cavities in the photoreceptor layer and retinal thinning (Fuijkschot
et al., 2008; Gualino et al., 2005; Mauget-Faysse et al., 2006).
However, no similar vascular changes have been shown in the few
available angiographic reports of these conditions (Gualino et al.,
2005; Willemsen et al., 2000). Notably, funduscopy in such
patients may reveal crystalline deposits as in MacTel type 2
(Drenser et al., 2006). Moreover, patients with SjögreneLarsson-
Syndrome showed a complete lack of macular pigment (van der
Veen et al., 2010) suggesting a similar pathophysiological process
as in the localized areas of macular pigment loss in patients with
MacTel type 2 (see Chapter 6.5). The medical history or, in patients
with SjögreneLarsson-Syndrome, concomitant syndromic symp-
toms, are usually helpful for the differential diagnosis.
12.4. Miscellaneous other diseases
In age-related macular degeneration, drusen are usually present
early in the disease course. Late disease stages are characterized bythe either geographic atrophy or neovascular membranes origi-
nating from the choroidal vasculature (in contrast to the primarily
retinal origin of neovascular complexes in MacTel type 2).
Further macular alterations that may be considered in the
differential diagnosis of selected cases are Irvine-Gass syndrome in
pseudophakic patients, solar retinopathy which may present with
a yellowish foveal lesion on funduscopy and atrophic changes
within the foveal photoreceptor layer on OCT imaging, other
diseases with crystalline retinal deposits (Drenser et al., 2006)
including West African crystalline maculopathy that may show
similar crystalline deposits in the inner retina (Sarraf et al., 2003),
macular full thickness and lamellar holes, or epiretinal gliosis.13. Treatment
Various approaches have been investigated to treat MacTel type
2 (Table 4). Most available reports are single cases or retrospective
small case series, with no data available from larger controlled
prospective trials.
The slow progression of functional defects in MacTel type 2
(Fig. 9) makes it difﬁcult to measure treatment effects particularly
over short periods of time. Outcome parameters different from
visual acuity assessment, such asmicroperimetry or enlargement of
areas of photoreceptor loss on OCT appear more suitable for
monitoring treatment effects in MacTel type 2 (see Chapters 8 and
9). Only few publications with small patient numbers have re-
ported such parameters. Moreover, short term effects such as
improvement in visual acuity after intravitreal application of bev-
acizumab (see below) may be due to the temporary decrease of
neurosensory edema without affecting the natural history of the
disease course, i.e. the slowly progressive photoreceptor atrophy.
Therefore, due to insufﬁcient information, general recommenda-
tions concerning the treatment of MacTel type 2 cannot currently
be made.
Since the potential gain of function after any treatment might be
limited by pre-existing neurosensory atrophy, initial thorough
phenotypic and functional characterization is most important. The
timing of intervention may be crucial since any treatment might be
ineffective once neurosensory atrophy or ﬁbrosis have occurred.
This chapter is divided into treatment approaches for non-
proliferative and proliferative phases. A separate paragraph in
Chapter 5 summarizes reports of treating macular holes in eyes
with MacTel type 2.13.1. Nonproliferative stage
Despite individual observations of improvement after focal
argon laser photocoagulation for MacTel type 2 (Chopdar, 1978;
Hutton et al., 1978), most of the literature suggests no beneﬁcial
effect (Gass and Blodi, 1993; Kiraly and Nasemann, 1995; Lowe
et al., 1998; Park et al., 1997). Park and co-workers retrospectively
analyzed the long-term outcome (median follow up time: 73
months) in 10 eyes of 8 patients. Visual acuity did not change
signiﬁcantly and a reduction of macular edema was only achieved
in 20% of treatments. Compared with untreated eyes, previous laser
photocoagulation was associated with distortion of retinal vessels,
more ﬁbrovascular tissue, retinal pigment epithelial clumping, new
draining venules and retinal hemorrhages. Argon laser photoco-
agulation for MacTel type 2 may be complicated by subretinal
hemorrhage (Friedman et al., 1993) and induction of new ﬁbro-
vascular membranes (Engelbrecht et al., 2002; Gass and Blodi,
1993; Park et al., 1996; Watzke et al., 2005). Therefore, because
no proven beneﬁt has been shown and because there may be an
increased risk for developing neovascular complexes, laser
Table 4
Overview of reported treatment approaches for non-proliferative and neovascular MacTel type 2.
Non-proliferative Neovascular
Conclusion References Conclusion References
Focal argon laser
photocoagulation
No improvement or stabilization.
Potentially worsens the disease
course and potentially induces
development of neovascular
membranes.
(Chopdar, 1978; Friedman et al., 1993;
Gass and Blodi, 1993; Hutton et al., 1978;
Kiraly and Nasemann, 1995; Lowe et al.,
1998; Park et al., 1997; Stoffelns et al.,
2010; Watzke et al., 2005)
Obsolete due to side
effects









(Hershberger et al., 2003;
Hussain et al., 2005; Potter
et al., 2002; Potter et al., 2006;
Shanmugam and Agarwal,
2005; Snyers et al., 2004;
Watzke et al., 2005)
þ Intravitreal steroids e e May support the
effect of PDT
(Smithen and Spaide, 2004)
þ Intravitreal VEGF
inhibition
e e (Rishi et al., 2008; Ruys
et al., 2007)
Intravitreal steroids Not clearly beneﬁcial, fading
effect over time, potential
side effects. Possible positive
effect in eyes with foveal
detachment.
(Alldredge and Garretson, 2003;
Cakir et al., 2006; Maguluri et al., 2007;
Maia Junior et al., 2006; Martinez, 2003;





(Arevalo et al., 2007)
Posterior juxtascleral
administration of steroids
No clear beneﬁcial effects (Eandi et al., 2006) May be beneﬁcial (Eandi et al., 2006)





Possible positive effect in eyes
with foveal detachment.
(Charbel Issa et al., 2008c; Charbel Issa
et al., 2011; Charbel Issa et al., 2007b;
Charbel Issa et al., 2007d; Charbel Issa
et al., 2010; Gamulescu et al., 2008;
Jonas et al., 2011; Kovach and Rosenfeld,
2009; Lira et al., 2010; Maia Junior et al.,
2007; Matsumoto and Yuzawa, 2010;
Matt et al., 2010; Roller et al., 2011;
Toy et al., 2012; Vianna et al., 2008;
Windisch and Kozousek, 2008)
Apparently beneﬁcial.
Larger and long term
studies lacking.
(Charbel Issa et al., 2007b;
Jorge et al., 2006; Karagiannis
et al., 2009; Konstantinidis
et al., 2009; Maia Junior et al.,
2007; Mandal et al., 2007;
Mavrakanas et al., 2009;
Mondal et al., 2010;
Narayanan et al., 2012;
Roller et al., 2011; Ruys




e e May be beneﬁcial (Shukla et al., 2004)
Vitreoretinal surgery Vitrectomy with internal
limiting membrane removal
not effective
(Sigler et al., 2012) Surgical membrane
removal obsolete
(Berger et al., 1997;
Davidorf et al., 2004)
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proliferative MacTel type 2.
Photodynamic therapywas used in two eyes of two patients with
non-proliferative MacTel type 2 (De Lahitte et al., 2004). In neither
patient did the authors observe signiﬁcant changes in visual acuity,
ﬂuorescein angiographic leakage or OCT ﬁndings.
Intravitreal injection of triamcinolone (IVT) has been reported to
reduce late phase hyperﬂuorescence in ﬂuorescein angiography
with (Martinez, 2003) or without (Alldredge and Garretson, 2003;
Cakir et al., 2006) an improvement of more than two lines in
visual acuity. Smithen and Spaide did not ﬁnd an effect on either
ﬂuorescein angiography or visual acuity (Smithen and Spaide,
2004). There appeared to be a reduction in retinal thickness
after IVT followed by a waning of the effect after nine months in
one report (Cakir et al., 2006). In the largest study reported to
date, the change in visual acuity of 19 eyes (14 patients) which
received one or two IVT injections was analyzed retrospectively
(Wu et al., 2008). After a mean follow-up of 21.2 months (range,
6e44 months), there was a gain and loss of 3 lines in 4 eyes each,
and a stable visual acuity in the remaining 11 eyes. IVT had
a beneﬁcial anatomical and functional effect in a MacTel type 2
patient presenting with bilateral foveal detachment (Maguluri
et al., 2007).
Posterior juxtascleral administration of anecortave acetate, an
angiostatic synthetic cortisol derivative supposedly without corti-
costeroid bioactivity, was reported to stabilize visual acuity over 24
months in two non-proliferative eyes. However, no data wereprovided with regard to the natural history in the fellow eye for
comparison, the angiographic effects, or alterations on OCT-
imaging (Eandi et al., 2006).
Short term observation after inhibition of VEGF using intravitreal
bevacizumab, resulted in a marked decrease of parafoveolar
leakage, normalization of macular capillaries and decrease in
retinal thickness. Visual acuity was reported to improve in few
patients (Charbel Issa et al., 2007b; Charbel Issa et al., 2007d; Toy
et al., 2012). Other studies have not found similar effects, possibly
because treated eyes hadmore advanced disease (Charbel Issa et al.,
2009a; Gamulescu et al., 2008; Kovach and Rosenfeld, 2009). As
a result of the chronic nature of the disease, the effect of the anti-
VEGF-treatment tended to wear off after two to four months
(Charbel Issa et al., 2008c; Toy et al., 2012). Further studies with
longer follow up identiﬁed a beneﬁcial effect of intravitreally
applied bevacizumab in patients who were treated on a pro re nata
(PRN) regimen over a mean follow up time of 18 (Charbel Issa et al.,
2008c) or 32 (Matt et al., 2010) months. Conclusions from those
studied are limited due to the small patient cohorts and the
retrospective study design. In two prospective studies on anti-VEGF
treatment for MacTel type 2, patients were treated monthly with
ranibizumab for one year (Charbel Issa et al., 2011; Toy et al., 2012).
At the end of those studies, there was no effect on visual acuity.
While the overall light sensitivity within the area of vascular
leakage might increase slightly (Toy et al., 2012), paracentral
photoreceptor atrophy and corresponding scotomata had pro-
gressed slowly despite a clear effect on the vascular alterations
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that monthly ranibizumab is not recommended for patients with
MacTel type 2. In view of the neuroprotective properties of VEGF
(Nishijima et al., 2007; Saint-Geniez et al., 2008), its constant
inhibition could potentially be harmful when treating a neurode-
generative disease such as MacTel type 2 in the long term.
A potential beneﬁt of short-term intravitreal VEGF inhibition on
foveal detachment in MacTel type 2 has been reported (Lira et al.,
2010; Maia Junior et al., 2007; Windisch and Kozousek, 2008).
The foveal anatomy regained its normal conﬁguration with
improved visual acuity in several retrospectively analyzed cases.
This observation needs further investigation in larger prospectively
designed trials.
A recent retrospective case series compared observation
(n ¼ 33) with intravitreal bevacizumab (n ¼ 15) or pars plana
vitrectomy (n ¼ 8) for non-proliferative MacTel type 2 (Sigler et al.,
2012). The authors found no difference in change of visual acuity
within a mean follow-up period of 24  13 months.
13.2. Proliferative stage
Various treatments have been used for subretinal neo-
vascularisation, which is a major cause of severe vision loss in
a minority of patients with MacTel type 2 (Engelbrecht et al., 2002;
Gass and Blodi, 1993; Yannuzzi et al., 2006). Park and co-workers
found little change in the size of the ﬁbrovascular tissue over
time and a ﬁnal visual acuity similar for eyes with and without
ﬁbrovascular tissue. This group consequently questioned the
usefulness of treatment in those eyes (Park et al., 1996). However,
Engelbrecht and co-workers reported that 80% of eyes with
proliferative MacTel type 2 had a ﬁnal visual acuity of 20/200 or
worse (Engelbrecht et al., 2002). Therefore, interventions might be
most beneﬁcial in early and active proliferative disease stages
before the development of ﬁbrotic membranes.
Visual improvement, stabilization and deterioration have all
been reported after argon laser photocoagulation. The resulting
scotoma and the potential to trigger further growth of neovascular
membranes would not favor this treatment approach, even if the
membranes were extrafoveal.
Photodynamic therapy (PDT) was ﬁrst reported in a patient with
recent decrease in visual acuity due to subretinal neo-
vascularisation. Visual acuity improved 2 lines after two treatments
and remained stable for seven months (Potter et al., 2002). Inter-
estingly, leakage from the neovascular membrane ceased after
treatment while parafoveal leakage typical for MacTel type 2
continued. Hershberger and co-workers needed ﬁve PDT sessions
and achieved an improvement of visual acuity from initially 20/160
to20/50 6months after the last PDTsession in one eye of one patient
(Hershberger et al., 2003). They noted a signiﬁcant and rapid
improvement in visual acuity following each treatment but also
a rapid reperfusion of the neovascular membrane following PDT-
induced closure. The group speculated that the ﬁrst may be
attributable to a relatively healthy pigment epithelium compared to
other diseases in which PDT is used, such as age-related macular
degeneration. The latter ﬁnding was explained by the high-ﬂow
anastomoses described in MacTel type 2. The largest series
studying PDT for neovascularMacTel type2, a retrospective analysis,
described seven eyes of six patients (Potter et al., 2006). An average
of 2.4 treatments were given according to a standard protocol (TAP-
Study-Group, 1999). Mean follow-up time after the last treatment
was 21months andmedian initial and ﬁnal visual acuity was 20/80.
More than 2 lines decrease or increase in visual acuity was observed
in one eye each while the other 5 eyes remained stable. Snyers and
co-workers reviewed 4 patients with neovascular MacTel type 2
treatedwith PDT (Snyers et al., 2004). In three patients, visual acuityremained stable at 20/30 and20/40 afterone, twoand three sessions
of PDT, respectively, within a follow up time of 23, 21 and 9months.
In one eye, leakage persisted even after 4 sessions of PDT and visual
acuity decreased from 20/50 to 20/200 despite absence of enlarge-
ment of the neovascular membrane. Hussain and co-workers
treated six eyes of three patients three times at shorter interval (2
months) than usual. All eyes in this series had stable visual acuity
after a median follow up time of 10 months (range 6e21 months).
The researchers noted associated retinal pigment epithelium
collateral damage in all six eyes of their study. There is the theo-
retical concernwith PDT forMacTel type 2 that the photosensitizing
drug may leak out of the retinal vessels in the macula and cause
harmwhen it is activated (Hussain et al., 2005; Potter et al., 2002).
Shanmugam et al. showed atrophy of the retinal pigment epithe-
lium (along with a decrease in visual acuity) corresponding to the
size of the laser spot (Shanmugam and Agarwal, 2005). However,
others did not observe any side effects (Potter et al., 2002, 2006).
Few cases of MacTel type 2 treated with PDT combined with an
intravitreal injection of either triamcinolone (Smithen and Spaide,
2004) or ranibizumab (Rishi et al., 2008; Ruys et al., 2007) have
been reported. Combined PDT and intravitreal triamcinolone for
neovascular MacTel type 2 resulted in an increase of visual acuity
from 20/200 to 20/50 (Smithen and Spaide, 2004). Re-treatment
due to recurrence of leakage was performed 9 months later and
visual acuity 3 months thereafter was 20/60. As an additional
ﬁnding, they reported a complete absence of telangiectasia after
treatment. However, intravitreal injection of triamcinolone alone in
the fellow nonproliferative eye revealed no marked functional or
angiographic effect. Combined PDT and intravitreal ranibizumab
injection was reported in two case reports. An improvement of
visual acuity from 20/125 to 20/60 and stabilization thereafter was
achieved within a follow up period of 9 months in one patient
(Rishi et al., 2008) and stabilization was achieved in the second
patient (Ruys et al., 2007). Only one PDT treatment with either one
(Rishi et al., 2008) or two (Ruys et al., 2007) intravitreal injections
were necessary.
Transpupillary thermotherapy (TTT) was used in an interven-
tional case series by Shukla et al. (2004). One and three months
after treatment, 46% and 85% respectively of 13 eyes showed
complete regression of the neovascular membrane. After a mean
follow up of 8.6 months (range 2e24.5 months), 12 eyes had
inactive membranes; 1 of these 12 required two additional
sessions of TTT. The median visual acuity remained stable
compared with baseline. While there was a stable (2 Snellen
lines) visual acuity in 11 eyes, one patient improved and one
patient worsened by 3 lines.
Posterior juxtascleral administration of anecortave acetate (15 mg,
6-month retreatment interval) in ﬁve eyes of four patients was
reported to result in stabilization or improvement of lesion size,
resolution of leakage, and stabilization of vision (Eandi et al., 2006).
One eyewith a very short history of visual deterioration showed the
best result with an increase of 3 lines in visual acuity within
a follow up period of 12 months. Three other eyes showed an
increase of two and one line or a decrease in one line within
a follow up period of 24months. Visual acuity did not change in one
eye that was last said to be stable 9months after the ﬁrst treatment.
Intravitreal application of VEGF-inhibitors has become the ﬁrst line
treatment for neovascular membranes due to age-related macular
degeneration (AMD). The concept of a similar pathogenesis of neo-
vascular AMD and MacTel type 2 was the rationale to study VEGF-
inhibitors as a treatment option for neovascular MacTel type 2
(Fig. 10; Charbel Issa et al., 2007b; Jorge et al., 2006; Karagiannis
et al., 2009; Konstantinidis et al., 2009; Maia Junior et al., 2007;
Mandal et al., 2007;Mondal et al., 2010; Roller et al., 2011; Ruys et al.,
2007; Shanmugam et al., 2007). Jorge and co-workers were the ﬁrst
Fig. 10. Effects of intravitreal bevacizumab therapy in neovascular MacTel type 2. A) Findings at baseline visit: Foveal hemorrhage in funduscopy (left, cf. Fig. 2B), due to neovascular
membrane with leakage in ﬂuorescein angiography (top, early phase; bottom, late phase). In microperimetry, there is a large absolute scotomawhich encompasses the foveal center.
Four months after one single treatment with intravitreal bevacizumab (B), the hemorrhage had been resorbed and leakage was reduced. The foveal center after treatment shows
only a relative defect and visual acuity has improved from 20/80 to 20/50.
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foveolar neovascular membrane (Jorge et al., 2006). They observed
improvement of vision from 20/40 to 20/20 at 24 weeks of follow-
up. Mandal presented a case series of six eyes of six patients
treated with intravitreally injected bevacizumab (Mandal et al.,
2007). The therapy was repeated at four weekly intervals if OCT
showed persistent intraretinal edema and/or subretinal ﬂuid. After
a mean period of 4.2 months (range 3e6 months), visual acuity had
improved by a mean of þ2.5 lines (range 0eþ6 lines) and all eyes
except one had two or more lines improvement. One eye without
functional improvement exhibited retinal pigment hyperplasia
involving the center of the fovea. More than one injection (n ¼ 2)
was only necessary in one eye. A decrease in retinal thickness and
leakage was demonstrated by OCT imaging and ﬂuorescein angi-
ography, the latter also showing diminuation of leakage from
telangiectatic vessels. Another retrospective case series (9 eyes) by
Roller et al. also concluded that anti-VEGF treatment may be bene-
ﬁcial for proliferative MacTel type 2. Within a mean follow up of 17
(9)months, 3 eyes improved2 lines, 2 eyesworsened by2 lines,
and in 4 eyes visual acuity remained stable at the last follow-up
compared with baseline. Patients needed 4.9 (4.3; range, 1e15)
injections. In a third retrospective case series, 16 treatment-naïve
eyes of 16 patients were treated with intravitreal ranibizumab or
bevacizumab monotherapy (Narayanan et al., 2012). A mean of 1.9
injections (range,1e3 injections) were needed during a mean follow
up time of 12 months (range, 3e43 months). Mean visual acuity
improved signiﬁcantly from 20/120 to 20/70. Most other smaller
case reports have demonstrated similar outcomes of intravitreally
applied bevacizumab on the activity of neovascular membranes in
MacTel type 2.
Surgical removal of subfoveal vascular membranes in MacTel type
2 could not be performed without also removing pieces of neuro-
sensory retina due to adherence of the membranes to the retinal
vasculature (Berger et al., 1997; Davidorf et al., 2004). Since the
functional outcome was unfavorable, it may be concluded that
subretinal surgery with current techniques is not efﬁcacious for
proliferative MacTel type 2.14. Perspectives
14.1. Natural history and disease progression
Since the landmark study by Gass and Blodi in 1993, little
knowledge has been added on the phenotypic and functional
changes of MacTel type 2 until recently. In the last several years,
however, a large number of previously unknown ﬁndings have
been identiﬁed by applying advanced imaging and functional
testing. Thorough and valid evaluation of disease progression will
be necessary not only to assess treatment effects in future thera-
peutic trials, but also to assess the natural history and eventually
generate a more reﬁned disease staging. Analysis of longitudinal
data using new tools for disease phenotyping will help to identify
outcome measures for interventional clinical trials as well as to
stratify patients regarding their risk for disease progression.
Longitudinal data will also reveal if patients can be stratiﬁed
according to different disease characteristics into subgroups of fast
or slow progressors, possibly according to different genetic back-
grounds or environmental factors. There may also be variation in
the individual pathophysiological response to the disease. For
instance, the chronic low grade leakage due to an impaired blood-
retinal barrier might trigger anti-retinal-antibodies in a subset of
patients which might subsequently develop a faster or different
disease progression.
The most widely accepted clinical endpoint in ophthalmology,
visual acuity, appears not to be a sensitive marker for progression of
MacTel type 2. Central retinal function, including distance visual
acuity, may remain relatively intact over substantial periods of time
even though other visual functions, such as reading ability and the
size of paracentral scotomata, deteriorate (Fig. 9). However, the high
variability of psychophysical testing results in difﬁcult veriﬁcation of
functional deterioration in a slowly progressing disease such as
MacTel type 2. Objective surrogate markers, e.g. derived from
imaging analysis and structure-function correlation, might be
helpful in this respect, at least for exploratory studies or for provi-
sional drug approval. Since not all structural changes over time are
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validated in independent studies against true clinical endpoints.
A recent interventional study illustrates how relying on certain
imaging modalities could be misleading in MacTel type 2: VEGF-
inhibition over one year resulted in regression of the vascular
alterations on ﬂuorescein angiography and visual acuity, after
a transient increase, was stable compared with baseline after one-
year (see Chapter 13.1) (Charbel Issa et al., 2011). However,
microperimetry rather showed a decrease in paracentral retinal
sensitivity and point-to-point structureefunction correlation
revealed that functionally relevant alterations within the photo-
receptor layer visible on spectral domain OCT progressed in treated
eyes (Charbel Issa et al., 2010). Therefore, despite the apparently
positive effect on ﬂuorescein angiography and visual acuity testing,
this therapy was not recommended. Notably, the atrophic changes
in the photoreceptor layer as the structural correlate of the retinal
sensitivity loss were already visible on spectral domain OCT before
their functional relevance could be detected by microperimetry
(Charbel Issa et al., 2010).
14.2. Understanding clinical ﬁndings
14.2.1. Macular pigment distribution and crystalline deposits
The reduced macular pigment density within the central retina
is one of the most striking features of MacTel type 2. The lack of its
function as a blue light ﬁlter could result in increased light damage
of macular photoreceptors. In MacTel type 2, a primary loss of
macular pigment due to defective trafﬁcking or storage (e.g. due to
dysfunctional transport proteins), or a secondary loss due to
pathology of the anatomical structures involved in macular
pigment accumulation, have been suggested. It remains to be
determined if macular pigment is simply reduced centrally or if
there is (additional) displacement of macular pigment towards the
periphery. The latter is suggested by the appearance on two-
wavelength fundus AF maps in advanced cases and by the signiﬁ-
cantly higher density at 8 eccentricity in a quantitative analysis
(Charbel Issa et al., 2009d). However, the sample size in that study
was small and there were no normal data available for 6 eccen-
tricity where the macular pigment density appears to be highest in
many patients with MacTel type 2. In a recent study, the total
amount of macular pigment was calculated using a more eccentric
reference area than the conventional 8 (Degli Esposti et al., 2012).
The authors found values comparable to normal controls, sug-
gesting that lutein and zeaxanthin are actually not lost from the
posterior fundus, but rather displaced laterally to a certain extent.
Longitudinal data studying the evolution and progression of
macular pigment loss in MacTel type 2 patients are so far lacking.
Since MacTel type 2 shares structural features with retinal
dystrophies, assessment of macular pigment density and distribu-
tion in patients with other macular dystrophies may help to further
understand thisﬁnding. Loss ofmacular pigmentmaybe considered
a secondary phenomenon if it occurs uniformly in unrelated
diseases. Recently, absence ofmacular pigment has been reported in
patients with SjögreneLarsson-Syndrome (van der Veen et al.,
2010). The known deﬁciency of fatty aldehyde dehydrogenase in
patients with this disease may suggest possible pathogenetic
pathways involved in the lack ofmacular pigment. Notably, patients
with SjögreneLarsson-Syndrome also showcrystalline deposits and
changes on OCT imaging (see Chapter 13.2) similar to those
observed in patients withMacTel type 2. Moreover, similar deposits
and OCT-changes have been reported for patients with Tamoxifen
retinopathy, for which no data on macular pigment distribution
have yet been published. Tamoxifen was suggested to inhibit
glutamate uptake into retinal pigment epithelial cells. Increased
concentrations of glutamate in the extracellular retinal space mightlead to excitatory toxicity with subsequent cell death. Experimental
data are available for Canthaxanthin retinopathy which also shows
similar crystalline deposits, although in a slightly different distri-
bution. In the monkey retina, the amount of the carotenoid
canthaxanthin and its metabolites in retinal tissue correlated with
the amount of ophthalmoscopically visible crystalline deposits,
strongly suggesting that these crystals indeed are due to a high load
of this carotenoid (Goralczyk et al., 2000, 1997). A histopathological
investigation of a human eye with canthaxanthin retinopathy also
suggested that carotenoids are involved in the pathogenesis of the
crystalline deposits (Daicker et al., 1987). Notably, there was also
atrophy of the inner parts of Müller cells (see Chapter 14.3).
Because the lack of macular pigment is localized and not abso-
lute, as in SjögreneLarsson-Syndrome, it is unlikely that a systemic
alteration leads to a primary loss of macular pigment in the retina
in MacTel type 2, although the involved area might be most
vulnerable to such an insult. It appears more likely that structural
alterations lead to a localized loss of macular pigment, which then
e hypothetically e may be converted into its crystalline form.
Further research into the pathophysiology of MacTel type 2 is
likely to beneﬁt research on the so far incompletely understood
mechanisms of macular pigment accumulation in the central
retina. Vice versa, a better knowledge of the physiological mecha-
nisms and anatomical structures involved in accumulation, traf-
ﬁcking and storage of lutein and zeaxanthin in the central retina
may shed light on the pathophysiology of MacTel type 2. Interest-
ingly, two binding proteins for macular pigments, namely Gluta-
thione S-transferase Pi isoform (GSTP1) for zeaxanthin and human
retinal lutein-binding protein (HR-LBP) for lutein were recently
identiﬁed (Bhosale et al., 2004, 2009; Li et al., 2011). Immunohis-
tochemical studies showed speciﬁc labeling for both binding
proteins of rod and cone inner segments, especially in the
mitochondria-rich ellipsoid region. Since OCT studies in patients
with MacTel type 2 suggested this retinal layer to be affected early
in the disease course (see Chapter 6.2), alterations in the meta-
bolically active compartment of photoreceptors (whether primary
or secondary) may play a major role in the pathogenesis of MacTel
type 2. Additional strong labeling with anti-GSTP1 was found in the
outer plexiform layer (Henle’s ﬁber layer). Recently, poly-
morphisms in the GSTP1 gene were looked at in MacTel type 2
patients but no obvious association was found (Parmalee et al.,
2010; Szental et al., 2010).
Questions to be answered with regard to the characteristic
distribution of macular pigment in patients with MacTel type 2 will
include: Does the expression of lutein and zeaxanthin-binding
proteins in photoreceptors point to a primary photoreceptor
disease? Are specialized Müller cells involved in the accumulation
and/or storage of lutein and zeaxanthin in the central retina? What
is the anatomic or physiological correlate that deﬁnes the charac-
teristic area of macular pigment loss?
14.2.2. Primarily neurosensory or vascular disease?
Hyporeﬂective atrophic cavities of the neurosensory retina have
been reported in patients with inherited retinal dystrophies
(Barthelmes et al., 2008b; Kellner and Kellner, 2009; Mahajan et al.,
2009), suggesting a similar disease process also for MacTel type 2.
With regard to the inner hyporeﬂective cavities, there may be a loss
of retinal structural integrity possibly similar to X-linked reti-
noschisis. In the absence of a bullous central retinal schisis, OCT
ﬁndings in X-linked retinoschisis may actually resemble those in
MacTel type 2 (Gerth et al., 2008; Gregori et al., 2009), and the
respective knock-out mouse model reveals pathologic features
reminiscent of MacTel type 2 (Weber et al., 2002).
The atrophy of the outer neurosensory retina which is primarily
supplied by the choroid, the localized loss of macular pigment
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disease, and the larger size of areas of macular pigment loss
compared with angiographically visible vascular alterations all do
not support a primarily vascular disease process. The eponymous
and characteristic ectatic parafoveolar capillaries may represent
a secondary phenomenon, e.g. due to localized metabolic and/or
oxidative stress within the outer retina that could result in an
increased expression of VEGF. This could lead to the development of
ectatic and sprouting capillaries along a concentration gradient
towards the outer retina. A medical history that may lead to similar
vascular alterations (e.g. diabetic or radiation retinopathy) and that
may render capillaries especially sensitive to the effects of VEGF
might predispose to such vascular telangiectatic alterations.
Accordingly, some studies identiﬁed diabetes mellitus, a patholog-
ically decreased glucose tolerance as well as a history of radiation
exposure to be associated with MacTel type 2 (Chew et al., 1986;
Maberley et al., 1999; Millay et al., 1986). It may be speculated that
similar neurosensory atrophic alterations may occur with varying
vascular alterations depending on additional factors that modify
the susceptibility to develop the vascular phenotype.
14.2.3. Area of disease manifestation
Several hypotheses were put forward to explain the restriction
and/or predilection of the MacTel type 2-associated pathology to
the peculiar area that it affects. For instance, it was suggested that
the presence of more numerous arterio-venous crossings temporal
to the fovea compared with nasally might give rise to chronic low
grade congestion or venous stasis of the temporal paramacular
capillaries (Gass and Oyakawa, 1982). However, a similar vascular
pattern was identiﬁed in 43 of 54 randomly selected control eyes.
Watzke et al. (2005) suggested a developmental origin based on the
ﬁndings that the vessels in the temporal paramacular area were
formed by anastomoses of superior and inferior vessels and not by
extension, as were all other retinal vessels (Nishimura and
Taniguchi, 1982). This could cause structural abnormalities with
subsequent decompensation of these vessels in adult life.
The reason for the temporal predilection may not necessarily be
found in the retinal vasculature. If the vascular alterations are
a secondary feature in the pathophysiology of the disease, any
proposed mechanism would have to explain why a primarily
atrophic disease process would be restricted to ormost pronounced
within this area. Notably, the retinal area involved in MacTel type 2
is similar to the localization of changes in other macular dystro-
phies without vascular pathology (Kurz-Levin et al., 2002;
Michaelides et al., 2007). The underlying cause for the affection of
this particular area as well as the temporal predilection is, however,
still unknown.
14.3. The role of Müller cells
Through the extensive arborization of their processes, Müller
cells provide nutritional and regulatory support to both retinal
neurons and vascular cells. They are intimately connectedwith cone
photoreceptors throughmicrovilli extending fromtheouter limiting
membrane. In the glycolytic pathway, Müller cells convert glucose
into lactate which they supply to the highly energy-demanding
photoreceptors. In retinal disease, Müller cells may protect photo-
receptors through the release of neurotrophic factors, such as nerve
growth factor (NGF), brain-derived neurotrophic factor (BDNF),
neurotrophins (NT-3 and -4) and ciliary neurotrophic factor (CNTF)
and the antioxidant glutathione (Bringmann et al., 2009, 2006).
They express GLAST, the predominant transporter within the retina
for the removal of the excitotoxic neurotransmitter glutamate.
Müller cells are also involved in the formation and maintenance of
the blooderetinal barrier (BRB), which they may inﬂuence by thesecretion of other factors such as pigment epithelium derived factor
(PEDF) and VEGF (Bringmann et al., 2006). The involvement of
Müller cells in supporting both neurons and vasculature suggests
that their dysfunction may be a central, although not necessarily
primary, feature of MacTel type 2, which is characterized mainly by
dysfunction of these two retinal elements.
Results from a clinico-pathological analysis of a pair of eyes
obtained post mortem from a conﬁrmed case of MacTel type 2
(Powner et al., 2010) support this hypothesis (see Chapter 11). The
distribution of loss of Müller cell speciﬁc immunohistological
markers correlated closely with the loss of macular pigment,
a phenotypic hallmark in patients with MacTel type 2. Macular
pigment is located in Henle’s layer (Snodderly et al., 1984a, 1984b;
Trieschmann et al., 2008), but whether it is associated with nerve
ﬁbers of photoreceptors or Müller cell processes remains unknown.
Macular pigment appeared to persist when primate photoreceptors
were ablated by subretinal alpha-aminoadipic acid in a primate
study, suggesting that at least some of the pigment may reside in
Müller cells, which were relatively unaffected in this model (Shen
et al., 2011). Analysis of the central retina from the fellow eye of
this pair using proteomic techniques revealed reduced levels of
Müller cell-speciﬁc proteins, including glial ﬁbrillary acid protein,
vimentin and glutamine synthetase (Len et al., 2012).
A number of clinical features of MacTel type 2 could be consis-
tent with a central Müller cell defect. As mentioned above, some
observations suggest e albeit circumstantially e that loss of
macular pigment could be associated with Müller cell dysfunction.
Loss of retinal transparency might also be associated with Müller
cell dysfunction, particularly if they act as light pipes that transmit
light through the retina as suggested by Franze et al. (2007).
Further studies, including the development of appropriate
animal models (see below), are warranted to test the hypothesis
that Müller cell loss and/or dysfunction may play a causative role in
the pathogenesis of MacTel type 2.
14.4. Animal models
Due to their apparent role in the disease pathophysiology,
Müller cells became a target in the development of new animal
models for MacTel type 2, Shen et al. generated a transgenic mouse
model of conditional Müller cell ablation using a Müller cell-
speciﬁc promoter to drive the expression of an attenuated form
of diphtheria toxin fragment A (DTA176). The retina in this model
showed a rapid photoreceptor apoptosis, vascular telangiectasia,
a blooderetinal barrier and breakdown later also deep retinal
neovascularization (Shen et al., 2012). Khalid et al. reported the
effect of Müller cell drop out after cell-speciﬁc transduction of
a gene expressing an inducible toxic protein (Khalid FI, IOVS 2012,
ARVO E-Abstract #1640). The procedure resulted in structural
damage and compromised retinal function. Thus, both mouse
models of Müller cell ablation showed ﬁndings reminiscent of
MacTel type 2 in humans.
Other animal models with similar retinal alterations may add to
the understanding of the pathogenesis of MacTel type 2. Transgenic
mouse models with over-expression of VEGF in photoreceptor cells
share overexpression of VEGF as well as neurosensory alterations
similar to the ﬁndings in patients (Lai et al., 2005; Okamoto et al.,
1997; Tobe et al., 1998; van Eeden et al., 2006), including outer
retinal degeneration, ectatic capillaries, sprouting of retinal vessels
into the outer neurosensory retina, angiographically detectable
leakage fromretinal vessels andneovascularmembranes originating
fromthesamevasculature. Amousewithadefect in thegene forvery
lowdensity lipoprotein receptor also develops some features similar
toMacTel type 2 (Dorrell et al., 2009;Heckenlivelyet al., 2003). Deep
retinal neovascularisation arising from the retinal vasculature is
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the neovascularisation was inhibited by both antioxidants and cell-
based delivery of neurotrophic factors (Dorrell et al., 2009).
14.5. Potential therapeutic approaches
Since loss of photoreceptors appears to be themain cause for the
loss of vision in MacTel type 2, treatment to prevent progression of
the condition may be aimed at preventing photoreceptor loss.
Ciliary neurotrophic factor (CNTF) is one of several neurotrophic
factors that are produced endogenously by Müller cells. Several
studies have suggested that CNTF may be potentially therapeutic
for retinal disorders (MacDonald et al., 2007). It has been shown to
protect the photoreceptors from degeneration in a variety of animal
models of retinitis pigmentosa, such as rd mice (Cayouette and
Gravel, 1997; LaVail et al., 1998), rds/rds mice, 334ter-3 rats,
334ter-4 rats, P23H-1 rats, Rdy cats and rcd1dogs (Bok et al., 2002;
Cayouette et al., 1998; Chong et al., 1999; LaVail et al., 1998; Liang
et al., 2001; Tao et al., 2002). There is already evidence that CNTF
might be beneﬁcial in human retinal degenerative disease as shown
recently in a phase Ib trial in retinitis pigmentosa (Sieving et al.,
2006). Currently, a phase 1b clinical trial is underway to investi-
gate the safety of intravitreal CNTF for the application in MacTel
type 2 (ClinicalTrials.gov Identiﬁer: NCT01327911).
15. Summary and future directions
Macular telangiectasia (MacTel) type 2 is a neurodegenerative
disease affecting the central retina. There has been remarkable
progress in characterizing the disease and revealing its patho-
physiology. General progress in phenotyping and therapy for retinal
disease has helped tremendously to study MacTel type 2. Examples
are imaging studies using high-resolution OCT and confocal laser
scanning ophthalmoscopy, fundus-controlled perimetry, and
intravitreal pharmacotherapy. So far, no therapy has been shown to
be efﬁcacious to modify the slow photoreceptor loss characteristic
for the disease. While efﬁcacy of anti-VEGF therapy has not been
shown in the non-proliferative disease, there may be a beneﬁt for
patients with neovascular disease manifestation. MacTel type 2
shows some unique features such as a central reduction of macular
pigment and hyporeﬂective cavities at the level of the inner and
outer retina as observed with high-resolution OCT imaging. Such
characteristic features provide further clues for the development of
future therapy. Since the condition appears to be primarily
neurodegenerative in nature, therapeutic interventions with
compounds that have neuroprotective properties appear prom-
ising. An interventional clinical trial in Mactel type 2, making use of
neuroprotection is currently underway.
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